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CHARACTERIZING THE EFFECTS OF HIGH-INTENSITY EXERCISE ON 
BALANCE AND GAIT UNDER DUAL-TASK CONDITIONS IN 
PARKINSON’S DISEASE 
ELISE IVA BARON 
ABSTRACT 
 
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by four 
cardinal motor symptoms including bradykinesia, tremor, rigidity, and postural 
instability, and non-motor symptoms including cognitive impairment. Daily activities, 
such as walking and maintaining balance, are impacted due to impairments in motor 
function, and are further exacerbated with the addition of cognitive loading, or dual-
tasking (DT). High-intensity exercise has demonstrated centrally-mediated improvements 
of PD symptoms, with additional positive effects on overall health.  
The goal of this project was to identify changes in dynamic balance recovery and 
gait function under conditions with and without increased cognitive load after a high-
intensity exercise intervention in a PD population. Participants included people with PD 
who completed an eight-week cycling intervention (PDE), people with Parkinson’s 
disease who did not complete the intervention (PDC), and healthy age-matched controls 
(HC), with 14 subjects per group. In Aim 1, while participants underwent a series of 
destabilizing balance tests, the time taken to regain balance and the center of pressure 
movement during balance recovery were measured. The PDE group demonstrated greater 
improvement in balance recovery after exercise compared with the PDC group. In Aim 2, 
participants completed a series of gait and cognitive tasks, both separately and 
concurrently. Outcome measures included spatiotemporal and kinematic gait parameters 
 vii 
 
of the lower and upper extremities. The PDE group demonstrated significant 
improvement in gait measures and DT abilities compared to PDC, while no changes were 
found in cognitive function for any group. 
 The standard clinical methods of measuring motor function can be subjective, and 
may not capture subtle motor characteristics. Force plate and motion-capture 
technologies can provide detailed, objective outcome data, therefore improving the 
understanding of how exercise affects motor symptoms of Parkinson’s disease. The 
Motek Computer Assisted Rehabilitation Environment (CAREN) system at the Cleveland 
Clinic was used to create the testing environment and for data collection.  
 These results of this project suggest global changes in motor function 
demonstrated by changes in balance recovery and lower and upper extremity gait 
function. Quantitative gait analysis has shown to be an important metric in assessing 
effectiveness of an exercise intervention in PD. 
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CHAPTER I 
INTRODUCTION 
1.1 Parkinson’s Disease 
 James Parkinson identified a movement disorder marked by flexed posture, 
resting tremor and shuffling gait. He termed this disorder “shaking palsy,” and published 
his findings in 1817. This disorder was later named after him, and research on 
Parkinson’s disease (PD) has continued since [3]. It was not until nearly a century later, 
in 1914 when Frederic Lewy discovered cytoplasmic inclusions in the brains of people 
with PD (now known as Lewy bodies) [4] and in 1919 when Konstantin Tretiakoff 
discovered lesions in the substantia nigra [5] that we began to understand the cause of 
Parkinsonian symptoms. In 1959, Arvid Carlsson published his findings that dopamine, 
not serotonin as previously thought, was deficient in the brains of Parkinson’s patients 
[6]. These neurological discoveries are the foundation for what we know about 
Parkinson’s disease today. 
 With the advancement of scientific discoveries, the description of Parkinson’s 
disease has expanded to include additional symptoms and greater pathological detail (See 
Table 1). Symptoms are categorized as motor or non-motor, and patients exhibit some, 
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but not necessarily all of these symptoms. Parkinson’s disease is unique to each 
diagnosed individual, and can vary greatly.  
 
The four cardinal symptoms of Parkinson’s disease include resting tremor, 
bradykinesia, rigidity and postural instability [10]. Although disease presentation and 
progression is unique to every patient, these symptoms are typically the first to appear 
[3].  Unlike resting tremor - which dissipates during active movements - bradykinesia, 
rigidity, and postural stability deficits permeate daily activities, impacting quality of life. 
In Parkinsonian gait, for example, rigidity and bradykinesia often manifest as decreased 
walking speed [11]–[19], and postural abnormalities [10]. Deficits in postural stability 
Table I – Parkinson’s disease symptoms 
Motor/Non-
motor 
Symptom Description  Reference 
Motor Resting tremor  Tremor of a limb when not in action  [3]  
Motor Rigidity Stiffness of movement [3] 
Motor Bradykinesia Slowness of movement [3] 
Motor Stooped posture Flexion of torso and/or limbs [3] 
Motor Postural response issues Improper balance reactions [7]  
Motor Freezing of gait Inability to step, usually at gait initiation  [3] 
Motor Festinating gait Short, quick steps [8]  
Motor Masked face Lack of facial expression [8]   
Motor Postural instability Balance issues [8] 
Non-motor  Personality and behavior 
changes 
Depression, fear, anxiety, passivity, 
dependence, apathy 
[3] 
Non-motor Cognition and mental Bradyphrenia (slowed thought process), 
dementia 
[3] 
Non-motor  
 
Sensory Olfactory loss, numbness, burning 
sensation, restless less syndrome, akathesia 
(restlessness) 
[3], [9]  
Non-motor  Autonomic function issues Hypotension, bladder problems, 
constipation, sexual dysfunction, seborrhea, 
dermatitis, sweating 
[3] 
Non-motor  Sleep issues REM sleep behavior disorder, excessive 
daytime sleepiness, altered sleep-wake 
cycle 
[3] 
Non-motor  Fatigue Tiredness  [3] 
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may induce compensatory tactics during gait such as increased double leg support time to 
increase stability during gait [12], [16], [17], [20].  
As the disease progresses and symptoms worsen, the consequences of the disease 
increase. Indirect costs, such as productivity loss, or early retirement accounts for 
approximately $1.7 billion in reduced national productivity [21]. The estimated 
prevalence of PD in the /United States is 0.3% in the population overall, with an 
increased rate of 1-2% in those 65 years of age and older, and 4-5% for those 85 and 
older. The financial burden of this disease can be estimated at $14.0 billion a year in the 
United States [21]. The incidence rate increases with age, and most rapidly after 60 years 
of age [22]. As the number of people 65 and older continues to increase, costs can be 
expected to increase as well [23]. 
Although Parkinson’s disease has no cure, treatments are available. Targeting 
brain function directly, dopamine replacement drugs and deep brain stimulation alleviate 
motor symptoms [3], [24]; however, side effects, such as dyskinesia (involuntary 
movements) [3], and risks of invasive surgery [24] accompany these treatment options. 
High-intensity aerobic exercise also aims to target changes in the brain, but is associated 
with lower risk and side effects. Animal models have shown significant symptom 
improvement from high-intensity exercise, and highlights several possible mechanisms 
for these results [25]–[27]. Human studies have also shown significant improvements in 
various measures, and are continuing to provide new information concerning the effects 
of different exercise parameters [28]–[31].   
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1.1.1 Parkinson’s Disease Neuropathology 
In a normal healthy brain, the basal ganglia, located at the base of the forebrain, 
are a collection of nuclei that are involved with various functions, voluntary movement 
control, procedural learning, cognition and routine behaviors [32]. The putamen, caudate 
nucleus, nucleus accumbens (collectively known as the striatum), globus pallidus 
(internal (GPi) and external (GPe)), subthalamic nucleus (STN) and substantia nigra 
comprise the basal ganglia. Excitatory and inhibitory signaling occurs between the nuclei 
in the basal ganglia, as well as to other areas of the brain (Figure 1). Dopamine - a key 
neurotransmitter involved in facilitating signal pathways - is produced by dopaminergic 
cells of the substantia nigra.  
 
Figure 1 – Signaling pathways connecting the basal ganglia (yellow box) and 
surrounding cortical and thalamic areas. In the “Parkinsonism” diagram, thin lines 
represent a decrease in signaling, thick lines represent an increase in signaling. Blue 
represents inhibitory signaling, red represents excitatory signaling. SNc, substantia nigra 
compacta; SNr, substantia nigra reticular; GPe, globus pallidus external; GPi, globus 
pallidus internal; CM/PF,VA/VL, thalamus; STN, subthalamic nucleus; PPN, 
pedunculopontine nucleus; SC, superior colliculus; LH, lateral habenula [33]. 
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The substantia nigra, located in the rostral midbrain, is comprised of two parts, 
compacta and reticular. The dopaminergic cells of interest are located in the substantia 
nigra compacta (SNc) which projects to the striatum. A simplified signaling pathway 
from the SNc to the motor cortex begins with dopamine produced in the SNc traveling to 
the striatum. From the striatum, inhibitory signals relay from the putamen to the GPe, 
inhibition from the GPe to the STN, excitation from the STN to the GPi, inhibition from 
the GPi to the thalamus, and excitation from the thalamus to the motor cortex. This 
activation modulates motor and cognitive functions. This entire process functions as a 
loop, with an signal originating in the cerebral cortex, modulated by the basal ganglia, 
and the appropriate commands sent back to the cortex for action initiation [34].  
The destruction of dopaminergic cells that occurs with Parkinson’s disease 
disturbs these pathways. The decrease in striatal dopamine leads to decreased inhibition 
from the GPe to the STN, therefore increasing excitation from the STN to the GPi, which 
leads to increased inhibition from the GPi to the thalamus, and decreased activation from 
the thalamus to the cerebral cortex [34], [35]. The dopaminergic signaling from to the 
striatum affects reward-seeking behavior and motor control functions [36], [37], which 
are markedly effected with PD. The symptoms manifesting from dopamine loss are listed 
above in Table 1. 
In addition to altered signal magnitudes in the dopaminergic pathways, people 
with PD also experience changes in signal firing patterns. Animal and human studies 
have shown abnormal oscillations of frequency in the GPi and STN, as well as abnormal 
synchronization of neighboring neurons [38]. Additionally, structural connectivity in the 
cortical and subcortical regions and their projections to other brain regions of PD patients 
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with cognitive impairment has shown to be significantly decreased compared to healthy 
controls [39]. Although decreased dopaminergic signaling from cell death in the STN 
defines PD and can explain most motor dysfunction, Lewy body aggregates present in 
non-dopaminergic brain structures also contribute to PD symptoms. Areas involved with 
acetylcholine signaling and production in particular (such as the pedunculopontine 
nucleus and the nucleus basalis of Meynert), can be adversely affected by Lewy bodies 
and are related to postural control and compensatory motor strategies in dynamic balance 
control [40]. These different functional breakdowns illustrate the complexity of the 
neurobiology of PD and the challenges faced in developing disease treatments.  
1.1.2 Motor Symptoms 
 Parkinson’s disease symptoms vary greatly across individuals, and are often 
characterized by two main subtypes: tremor dominant, and postural instability and gait 
difficulty. As the name suggests, the severity of tremor symptoms is greater than postural 
instability and gait severity in tremor dominant, and vice versa. These classifications are 
general, and mixed symptomology is common as well [41]. These subtyped may also be 
expressed at tremor or akinesia-dominant, and have similar categorical criteria to tremor 
or postural instability and gait difficulty groupings [42].    
1.1.2.1 Gait   
 Descriptions of Parkinson’s disease gait includes stooped posture and shuffling 
gait [3], which is the culmination of slowness of speed, reduced arm swing, reduced 
stride length and decreases in joint ranges of motion [14]. Although normal slowed gait 
speed involves smaller, slower steps, hypokinesia, bradykinesia and rigidity are the 
sources of gait declines in PD. Bradykinesia is the overall slowness of muscle 
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movements, while hypokinesia limits step size, therefore decreasing stride length. 
Rigidity increases muscle tone inappropriately, inhibiting the full speed and extension of 
limbs [40]. 
Compared to healthy controls, PD specific gait declines, known as shuffle gait, 
typically include decreased speed [11]–[19] and decreased step length [11], [12], [14]–
[19], yet no difference in cadence (steps per minute) [11], [13], [15], [16], [19]. These PD 
gait characteristics demonstrate a slowed walking speed attributed to shorter step length 
[12], [43], with increased double leg support time [12], [16], [17], [20] and increased 
stance phase [16], [44] representing gait stabilizing tactics. The kinematics of lower 
extremity joints often align with decreased step length and exhibit an overall decrease in 
range of motion (ROM) of the hip, knee, and ankle joints [11], [14]–[17], and typically 
inversely correlate with disease severity [11].  
Biomechanical analysis of PD gait includes studies with participants both “on” 
[18], [45], [46] and “off” [11], [17], [47] medication, and significant gait declines exist 
for those with PD compared to healthy peers under both conditions. However, the type 
and degree of severity of outcome measures in which changes are seen differs between 
“on” and “off” medicated state. For example, “off” medication, subjects may exhibit 
significant declines in joint ROM for most of the lower extremity joints [11], [16], [17], 
while “on” medication they may show significant declines in the ankle joint only [46]. 
When the same cohort of subjects are tested both “on” and “off” Parkinsonian 
medication, some studies have indicated that levodopa has shown to elicit improvements 
in spatiotemporal, such as velocity and stride length, and kinematic outcome measures, 
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such as joint ROM, [11], [19], [47], [48], while other studies have shown a lack of 
levodopa induced change in temporal measures such as cadence [48]. 
Differing responses to levodopa as well as information from healthy adults and 
animal model studies contribute to the understanding of the underlying mechanisms of 
Parkinsonian gait disturbances. Healthy gait function involves a combination of cognitive 
and automatic processes to initiate, continue, and augment gait and posture. The 
cerebellum regulates and integrates feed-forward cognitive processes from the cerebral 
cortex and sensory feedback processes from the spinocerebellar tract. The continual basic 
gait pattern is engendered by central pattern generators, which are a spinal neural network 
influenced by sensory feedback. The basal ganglia can also contribute to modulating gait 
processes, with the midbrain dopaminergic neurons influencing this effect [49]. In PD, 
loss of dopaminergic cells, reduced connectivity in areas responsible for motor 
automaticity and reduced activation in cortical areas contribute to gait declines. 
Dopaminergic cell loss can lead to bradykinesia and rigidity, and impaired automatic 
motor functions necessitate compensatory neural recruitment, yet decreased neural 
activity in cortical regions limits ones ability to effectively compensate with these areas 
of the brain [42], [50]. Additionally, gait function has shown to predict cognitive decline, 
highlighting the dependency of gait function compensation on cognitive function in PD 
[51].    
1.1.2.2 Arm Swing 
 Arm swing during gait is the pendulum motion of the arm traveling 
anteriorly/posteriorly in the sagittal plane. Patients with Parkinson’s disease often show a 
decrease in arm swing function compared to healthy peers, with decreased ROM for both 
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the elbow and shoulder joints [15], [52] decreased acceleration and increased asymmetry 
between the right and left arms [52]–[54]. Decreases in arm swing excursion are to be 
expected with decreases in velocity. However, characteristics observed in PD suggest 
changes at a centrally mediated, subcortical level, independent of gait speed.  Patients 
with Parkinson’s disease who demonstrate decreased or loss of arm swing typically 
experience these declines before lower extremity declines [55], and exhibit abnormally 
timed muscle activations, both in a rhythmic pattern and randomly [56]. Parkinson’s gait 
also experiences “phase shifting,” where the phases of the repetitive swinging motion of 
the arms and the legs are not aligned as with healthy controls [57], [58]. In instances 
where patients have an affected and unaffected side, the affected side (greater symptom 
presentation) typically shows lesser arm swing motion, while the unaffected side might 
not reach a significant difference compared to healthy controls [54], [59]. Furthermore, 
dopaminergic modulation has shown the ability to alter impaired arm swing by 
decreasing arm-to-arm swing asymmetry and increasing velocity in the affected arm [47], 
[59], and subthalamic nucleus stimulation has shown the ability to decrease phase shift 
and increase ROM [58].  
1.1.2.3 Balance 
 Postural stability is a key aspect of mobility and ambulation, and applies to static 
(such as stationary standing) and dynamic (such as walking, turning or responding to an 
external force) conditions. With PD, both static and dynamic balance is affected. 
Corrective muscular responses necessary to maintain an upright position under stationary 
or destabilizing conditions can become inaccurate in PD, resulting in declines in postural 
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stability and balance recovery [7], [60]–[62]. Poorly timed muscle activation driving 
bilateral coordination employed during walking, can also lead to instability [20], [63].  
 Balance is a combination of vestibular, visual and somatosensory inputs and 
regulation. The integration of modalities contributing to postural stability is impaired in 
PD, leading to instability [64]. Decreased connectivity networks in pathways to the 
occipital cortex [39] may impact visual processing, while disruption to the nigro-striato-
collicular tracts in PD are believed to cause vestibular disturbances [65], potentially 
contributing to postural instabilities [66]. Somatosensory input remains intact [67], 
however, abnormal processing leads to inadequate recognition of the placement and 
forces required for proper movement [64], and inappropriate scaling of response 
movements under dynamic balance challenges [64], [67]. Neural synapses outside of the 
basal ganglia and its direct projections are also impacted by PD. Acetylcholinergic areas 
of the brain are adversely affected by Lewy bodies in PD, and may affect reactive balance 
control [40]. Decreased muscle force production and disproportionally smaller reactions 
may be attributed to bradykinesia, while rigidity contributes to increased background 
muscle tone, inhibiting quick, reactive muscle movements [68]. The consequences of 
poor postural stability often lead to falls and injury. 
1.1.2.4 Fall Risk  
 As falls are common among older adults, they are more common amongst those 
with Parkinson’s disease due to overall motor impairments. Recent studies report that on 
average, 60.5% of people with PD report at least one fall, and 39% on average report 
recurring falls [69]. The risk for falls increases with inadequate reactive postural 
responses, gait declines and increased difficulties in DT conditions [70]. Recurring falls 
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are common to about 50% of those who have previously sustained one fall [71]. Falls for 
older adults pose a greater risk than a younger population, often resulting in serious 
injuries such as hip fractures, which are accompanied by costly hospital and rehabilitation 
visits [72]. In addition to physical and financial consequences, past falls may invoke a 
fear of future falls, and is a strong predictor of future falls in PD [73]. This fear of falling 
may potentially facilitate negative life changes, such as isolation and reduced physical 
activity [74]. Furthermore, a reduction in physical activity can lead to poorer health 
outcomes, and isolation can lead to decreased mental well-being [75].  
 The relationship between falls and physical activity in Parkinson’s disease is 
complex. An inverted U-shaped relationship between falls and disease severity is 
commonly seen in PD. At early disease onset with mild PD, falls tend to be infrequent; as 
the disease progresses to the moderate severity, falls increase; and towards the greatest 
disease severity falls return to infrequent. Ambulatory activity declines with age and 
disease severity, and has its own intricate relationship with fall risk [76], [77].   
 Characteristics of ambulation and motor function which decline in PD can be 
linked to increased fall risk, such as turning ability [78], retropulsion (loss of balance in 
the backward direction) [73], freezing of gait (inability to initiate walking, the feet seem 
“frozen” in place) [79], and poor balance recovery responses [7], [80]. Bradykinesia and 
rigidity pervasively alter motor tasks, and contribute to motor declines which increase fall 
risk [7], [68].  
 In addition to motor declines and their effects on fall risk, cognitive declines also 
show association with falls in PD. Increased incidence of falls has shown to correlate 
with increased cognitive decline [78], [81], and decreased brain volume in areas 
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associated with attention [81]. Falls and fall risk in people with PD remains complex and 
commands continued research in fall prevention. 
1.1.3 Non-Motor Symptoms 
In addition to motor function decline, people with PD experience a myriad of non-
motor symptoms, specifically cognitive function decline. The basal ganglia-thalamo-
cortical circuits responsible for motor function have parallel circuits responsible for 
associative/cognitive functions, which are also effected by impaired signaling in PD [33]. 
Executive function is mainly housed in the prefrontal cortex, and deficits in this area 
become apparent through cognitive decline [34]. Decreased dopamine in the striatum and 
its impaired connections to specific regions of the prefrontal cortex impact many of the 
executive functions that decline with PD [82]. The basal ganglia and prefrontal cortex in 
particular, play a role in allowing decidedly relevant information to be stored into 
working memory [83]. Decreased activity in the striatal and prefrontal regions leads to 
inappropriate signaling in the frontostriatal loop, resulting in declines in tasks measuring 
working memory, set-shifting, planning, attention and cognitive flexibility [82]. 
 Executive function declines in PD are detectible in various neuropsychological 
tests [84]. For example, the N-Back test assesses working memory [85], serial-7 
subtraction assesses attention and concentration, and the verbal fluency test assesses 
semantic memory [86]. These different cognitive functions are interwoven into daily 
tasks, and declines can significantly impair quality of life.  
1.1.4 Current Treatment Methods  
The conventional treatment methods for managing Parkinson’s symptoms that 
directly target the brain include dopaminergic medication and deep brain stimulation. 
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Delivering dopamine to the brain is complicated by the fact that dopamine cannot cross 
the blood brain barrier; therefore, the precursor levodopa is administered orally. To 
inhibit conversion of levodopa peripherally, prior to delivery to the central nervous 
system, carbidopa or benserazide is combined with levodopa. This combination increases 
the bioavailability of levodopa (and ultimately, dopamine) to the brain, and decreases the 
side effects (nausea, vomiting) of increased peripheral dopamine [87], [88]. Overall, 
levodopa medications improve motor and non-motor symptoms [47], [87], [89], 
including gait function [47]. Although medications do improve symptoms, they do not 
eliminate them completely. Gait parameters do not necessarily reach the values of healthy 
controls, even during the peak of a dose cycle [19], [47].  Other drugs, such as 
bromocriptine, pramipexole and ropinirole mimic the actions of dopamine in the brain to 
provide similar affects [47].  
In healthy individuals, dopaminergic neurons in the striatum metabolize, release 
and reuptake levodopa. With decreased dopaminergic neurons in PD, serotonergic 
neurons are recruited to convert and release levodopa. However, serotonergic neurons 
lack dopamine receptors and appropriate feedback, therefore leading to poorly timed 
dopamine release into the striatum contributing to motor side effects, such as dyskinesia 
(involuntary movements) [87]. Additionally, the risk for developing dyskinesia increases 
with earlier onset of the disease, as well as with higher cumulative levodopa medication 
doses [90].  
Deep brain stimulation is another effective treatment for PD, involving an 
implanted device providing electrical stimulation to the brain [91]. Different target 
locations are used, with each location of the electrodes targeting slightly different 
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outcomes. Subthalamic nucleus stimulation primarily improves motor function and can 
reduce the need for medication, GPi stimulation show improvements in mood and 
cognition [91], the thalamic ventrointermedial nucleus is targeted for decreasing tremor 
[92], and stimulation in the pedunculopontine nucleus region (PPN) targets decreases gait 
freezing and postural instability [93]. Although some reviews have identified these 
locations with targeted symptomatic relief, there is certainly overlap due to neural 
connections and projections, such as tremor treated by both STN and GPi stimulation, 
and improvements in gait function with STN and PPN. The most ideal stimulation sites 
for maximum symptom relief are still being investigated, with increasing emphasis on 
non-motor symptom relief [94]. Although some research has shown improvements in 
cognition, sleep and attention with PPN stimulation [94], other studies have shown that 
STN and GPi stimulation can result in declines in attention, memory and executive 
functions [91] and further research is needed in this area.  
 Medication and deep brain stimulation are effective treatment methods for PD, 
targeting brain function directly; however, the side effects of dyskinesia [3], [90], [95], 
fluctuating effectiveness of the medications [96], and risks of surgery such as cost, device 
malfunction [97], infection [24], [97] and decreased cognitive function [91] accompany 
these treatments options..   
1.2 Dynamic Balance - Perturbation Response 
 When an individual is destabilized by a sudden shift of balance, whether from an 
impact to the body, or a tilt or shift of the floor beneath them, the body responds in efforts 
to regain its balanced position. In addition to instinctual grasping reflex of the hands, the 
muscles and joints of the trunk and lower body react to shift the body to best support 
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itself. The muscular responses responsible for stabilization occur at different time points, 
typically characterized as short latency (occurring first), medium, then long latency 
(occurring last). It is believed that short latency responses are monosynaptic stretch 
reflexes occurring in the spinal cord, and medium and long latency responses involve 
muscle activations which induce balance recovery behaviors, such as grabbing for a 
stabilizing bar, and function under cortical influence [98], [99]. These responses usually 
involve flexion and extension of the ankle and hip joints to control anterior-posterior 
displacements, and lateral trunk flexion and weight shifting between the legs to regain 
control after lateral displacements [100]. One of two different strategies typically 
dominates at the ankle or the hip, each involving contraction of the surrounding muscles 
and motion at the joint [101]–[103], and is modifiable based on the most efficient option 
for the surrounding conditions [98]. The EMG muscle response pattern to a platform shift 
is typically a high EMG reading upon the initial movement, followed by tonic muscle 
contraction while the body is in motion with the moving platform [7], [60]. Both young 
and older healthy populations can appropriately scale their joint kinematics and kinetics 
to the magnitude of an induced perturbation to regain their balance [104], meaning 
muscle contractions and joint movements are directly correlated with the magnitude of 
the perturbation intensity.   
 Balance reactions for a PD population deviate from the healthy, normal patterns 
of balance recovery. Studies have shown differences in both muscle forces and activation 
timing. When analyzing muscle EMG’s, the muscles of the lower limbs can be broken 
into groups via their reflex activation times – short and long latency. In a backwards tilt 
or shift for example, the tibialis anterior acts as the antagonist muscle, has a long latency 
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response, and contributes to postural stability [99]. While short latency muscles exhibit 
similar timing for PD and for controls, the tibialis anterior has a delayed onset [62], 
[105]. Since the long latency response likely utilizes cortical control [98], [99], decreases 
in postural stability in PD may reflect declines in cortical function. In situations with 
varying degrees of tilt or shift intensity, PD patients exhibit difficulty scaling their 
reactions appropriately. Studies have shown that PD patients do not exhibit significant 
changes in measures such as rate of center of pressure (COP) excursion [106], joint 
motion [104], and EMG response [62], [105] across varying perturbation intensities 
[104], whether the level of intensity is known or unknown [62], [105], [106]. Often, the 
active EMG response amplitudes are smaller than controls [7], [105], yet background and 
passive EMG activity is larger [7], [60]. Center of mass displacement is also typically 
greater than controls, while COP displacement is often smaller, indicating instability as 
the closeness of these two measures is necessary for proper stability [61], [107]. 
Bradykinesia and rigidity may be responsible for the inability to scale responses properly 
and inappropriate muscle activation [61], [68]. Dopaminergic medication alleviates 
rigidity; however, this results in decreased muscle tone and a worsening in perturbation 
response abilities [68].   
1.3 Cognitive-Motor Dual-Task 
 Performing two simultaneous tasks requires a greater cognitive load than either 
task performed alone. Cognitive-motor dual-tasks (DT) can be effective in understanding 
task prioritization when mental resources are limited. Dual-task costs describe the effects 
of a DT paradigm compared to each task performed individually as a single-task (ST). 
Dual-task paradigms are sensitive enough to show both motor and cognitive dual-task 
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costs in healthy young adults [108], yet versatile enough that they have been used 
extensively with compromised populations. 
 Subjects with Parkinson’s disease generally exhibit greater dual-task costs than 
healthy control subjects [109]–[112]. The manifestations of costs affecting gait include: 
increased gait asymmetry, slower, shorter steps, increased double support time [113], 
differences in gait profile, variability in torso and lower extremity joint rotations, [114], 
and decreased arm swing [115]. 
 In dual-task tests, individuals tend to prioritize one task over the other. The 
“posture second” strategy – that individuals will allocate their attention primarily to the 
cognitive task in a dual task scenario and experience declines in motor or posture – is 
commonly observed in PD [20], [114], [116], [117]. However, other studies have shown 
conflicting results where prioritization varies, often depending on secondary task type 
[109], [118], [119].  
 Cognitive tests commonly utilized in dual-task paradigms include Stroop (both 
auditory and visual), serial subtractions, spontaneous speech, text comprehension and 
phoneme counting. Studies have shown variability in dual-task cost significance across 
different cognitive tests. For example, comparing the auditory Stroop test and the 
spontaneous speech test while walking in older adults, the spontaneous speech dual-task 
resulted in greater effects on gait parameters [120]; and comparing a serial seven 
subtraction test and the visual Stroop, the serial-7 subtraction test showed greater effects 
on trunk measurements [121]. Comparing tasks with phoneme counting, text 
comprehension and serial seven subtractions, only the serial subtractions test showed 
significance in dual-task costs [109]. Although the purpose of these tasks under DT 
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conditions is to provide excessive cognitive loading, they all address different aspects of 
cognitive function which likely contributes to differing results.  
The exact changes in signaling pathways in PD under DT conditions are 
unknown; however, recent studies suggest activation extending beyond areas directly 
related to the tasks at hand. These misdirected signals may illustrate the decreased 
organization of neural signaling, impacting DT function [122], [123]. 
1.4 Technology 
 Detection of changes in motor function can be important in diseased populations 
for identifying disease progression and monitoring the impacts of intervention [124]–
[126]. As technology has advanced, more objective measures have become available to 
analyze gait parameters, increasing the detailed understanding of gait and balance and 
how it is related to physical and neurological pathologies. Some of these technologies 
include force plates, inertial sensors and motion capture [127]–[129]. Integrated 
technology systems, such as the Motek Computer Assisted Rehabilitation Environment 
(CAREN) system [130] combines technologies to maximize objective data collection.  
1.4.1 Basic Principles of Motion Capture 
Motion capture can be broken down into two essential parts: determining the 
location of an object in space, and the changes in position of the object over time. The 
first step, determining object location, involves motion capture cameras, the objects in the 
space (often markers), and a series of equations. The process involves taking an object in 
3-dimensional space, gathering information about its location in 2D space, and 
reconstructing it onto a virtual 3D coordinate system. This is accomplished by using a 
series of equations called projection equations. The point in space projects its image onto 
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the camera lens creating a 2D image, accounting for the focal length, location, and 
orientation of the camera relative to the space. Multiple cameras placed around the 
motion capture space each collect a different image to discern the third dimension, 
similarly to how stereopsis (binocular vision) of human eyes creates our perception of 
depth [131]. Although it is possible to determine a marker location with two cameras, 
three or more cameras are recommended for best results. To decrease the possibility of 
marker occlusion, a greater number of cameras are used. With limited views of the 
capture volume, markers can become out of sight (dropped), or incorrect markers can 
appear where there is actually no marker (“ghost”). For example, if two markers lay in 
the same horizontal plane, and their lines of sight to separate cameras cross, it may 
appear that there is only one marker in the crosshair instead of two separate markers (see 
Figure 2) [132]. Combining the information from the different camera views, a least 
squares method equation can solve for the three unknowns: the x, y, and z positions of the 
markers. These positions are calculated for every frame, and the changes in position over 
time translate to motion. 
 
 
Figure 2 – Example of possible “ghost marker” configuration 
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 When describing the location of objects in the capture volume space, two 
coordinate systems are used: global and local. The global coordinate system can be 
defined different ways, but it essentially describes the objects in the “original position”. 
This may be defined in relation to the ground in the space volume, or as the marker 
location in the first recorded frame. The local coordinate system is defined as the new 
marker position after a rotation and/or translation in space, in relation to the new position. 
Detecting motion relies on a mathematical relationship between the global and local 
coordinate systems, see Figure 3. 
 
 
 
Figure 3 – Calculating the relationship between two joint segments. This involves 
comparing the relationship between the global-to-local transformation matrices of each 
segment. 
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With a motion capture system such as Vicon, the marker coordinates in the x, y, 
and z planes are provided per timestamp (the number of timestamps per second depends 
upon sampling frequency). Using this data, transformation matrices are created, 
containing the rotation and translation information of each object in 3-dimensional space 
from one timestamp to the next. To calculate relationships between body segments such 
as joint angles, the transformation matrix relating the local coordinate system of the first 
segment to the global coordinate system is created. Next, the transformation matrix 
relating the local coordinate system of the second segment to the global coordinate 
system in created. Finally, an equation describes the relationship between the two local-
to-global transformation matrices of each frame (see figure 5) [133]. Motion capture for 
the human body often uses the coordinate system of the pelvis as the global coordinate 
system, and the coordinate system of the segment of interest as the local coordinate 
system [134]. 
To compute the angles between two objects such as the upper and lower arm 
segments, the rotation matrix (part of the transformation matrix) is decomposed into x, y, 
and z rotations, and the angles are extracted individually from matrix equations [135]. 
The order in which these rotation matrices’ calculations are applied is significant. When 
measuring anatomical joints, this “joint angle sequence” will vary depending on which 
joint is being measured, following the individual joint rotation pattern of 
flexion/extension first, medial/lateral second, and interior/exterior rotation last [134].   
1.4.2 Instrumentation (CAREN system) 
 Study assessment and data collection took place on the Motek CAREN system. 
Located on the Cleveland Clinic’s main campus, CAREN is an integrative motion 
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capture system, consisting of a Vicon 10-camera real-time motion capture system, a 
Moog motion base platform with six degrees of freedom, a dual-belt treadmill with two 
Forcelink force plates (one located underneath each belt), a 180-degree cylindrical 
projection screen system, surround sound, and D-Flow software (see Figure 4).  
 
Figure 4 – The Computer Assisted Rehabilitation Environment (CAREN) system at the 
Cleveland Clinic, Cleveland Ohio. 
 
 
Various data are collected from the system and are sent to D-Flow for processing. 
These inputs are processed within module-based applications and allows for real-time 
feedback. D-Flow provides a library of modules, each possessing unique qualities and 
functions. Data streams into these modules and different connections between modules 
process the data for output functions, calculations, changes to the system, etc (see Figure 
5). 
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Figure 5 – The flow of information through the CAREN system. The marker data from 
the cameras is processed through Vicon and sent to the giganet computer to combine with 
force data from the force plates. This information is processed in D-flow according to 
programmed specifications. The outputs from the D-flow application can program 
platform movement, treadmill speeds, and images on the screen.  
 
 The motion capture aspect of the CAREN system includes a passive marker 
system and force plates. The motion capture system includes Vicon MX-T cameras, 
which consist of a digital video camera, a strobe head unit, a lens, and optic filter. The 
strobe unit consists of LED’s (Light Emitting Diodes) that shine infrared light on the 
retroreflective spherical markers, which then reflect the light beam back to the cameras. 
The force plates have six load cell sensors per plate - three in the Y direction (vertical), 
two in the X direction (horizontal left-right), and one in the Z direction (horizontal 
forward-backward). Two video cameras are also located on the rear-left and right of the 
treadmill to capture live video. The video does not affect the data flow of the system, and 
therefore was not included in the diagram (Figure 5).  
 24 
 
1.5 Exercise and Parkinson’s Disease 
 Exercise results in various positive effects on people with Parkinson’s disease, 
including improvements in motor and non-motor functions [136]–[139]. Changes in 
functions not directly related to the exercise task are of particular interest, as they suggest 
centrally mediated changes at the cortical and subcortical areas of the brain. In gaining 
understanding of the effects of exercise on the brain, animal studies provide valuable 
insight, and have set a foundation for this area of research.  
1.5.1 Animal Models 
 To induce Parkinson’s-like physiology in mice for animal models, 6-
hydroxydopamine (6-OHDA) is commonly injected to facilitate nigrostriatal neuronal 
loss. Tillerson et al. discovered that increased use of limbs impaired by 6-OHDA 
injection results in decreased loss of function as well as decreased loss of dopamine 
located in striatal tissue [140]. Additionally, decreased used of the affected limb resulted 
in the opposite: increased loss of function and increased loss of striatal dopamine [141]. 
These studies contributed to the foundation for investigating the neuroprotective role of 
physical activity on PD. Subsequent animal studies have shown that high-intensity 
exercise (typically treadmill running) in PD mice results in neuroprotective effects, 
changes in neurotransmitter transport, and increases in neurotrophins [25]–[27], [142]–
[147]. The neuroprotective effects include increased defense from oxidative stress and 
support of angiogenesis and synaptogenesis [25]. In addition to symptom improvement, 
exercise in PD mice results in increases in dopamine D2 receptor mRNA, and significant 
decreases in dopamine transporter [26], [27], decreasing dopamine reuptake into 
presynaptic vesicles. With increased dopamine receptors and increased postsynaptic 
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dopamine signaling, dopaminergic effects increase despite no differences in striatal 
dopamine levels in PD + exercise mice compared to PD control mice [142]. These results 
suggest that high-intensity exercise causes compensatory changes in the brain concerning 
dopamine processing. Studies have also found increases in neurotrophins such as brain-
derived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF) and 
insulin-like growth factors as a result of exercise [25], [143]. Furthermore, Gomez-Pinilla 
et al. demonstrated a positive correlation between BDNF and proteins involved in cellular 
metabolic processes [147]. The proteins include: AMPK which monitors energy levels in 
cellular metabolism [145], uMtCK which is involved with energy maintenance and 
transduction [144], and UCP-2 which regulates energy metabolism by uncoupling 
mitochondrial electron transport during ATP synthesis [146].    
1.5.2 Human Exercise Research 
 Methods of neuropathological data collection used in animal model studies are 
often invasive and result in subject sacrifice; therefore, alternative testing methods are 
employed for human studies investigating neurophysiological effects of exercise. 
Peripheral neurotrophic factors have been shown to increase from exercise interventions; 
however, this is not an exact measure of the neurotrophic factors in the brain [148]. Other 
methods to study brain activity, such as non-invasive fMRI tests have been used in 
human studies with cycling interventions [28], [149]. Physical outcome measures 
representing symptom improvement are also used to assess changes in a PD population 
due to an exercise intervention, such as the UPDRS assessment or accelerometers 
measuring tremor. Exercise programs with mixed tasks (such as cardiovascular, strength, 
balance, stretching, etc.) have shown improvements in motor function measured by the 
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UPDRS, improvements in walking [136], [137], and balance ability [136]. Forced 
exercise cycling studies have shown improvements post-intervention in UPDRS scores 
[29], [30], [149], tremor [150], manual dexterity and force [28], [30], and shoulder ROM 
[151]. Improvements in upper extremity function (a part of the body not actively involved 
in the exercise) and changes in brain activation following forced exercise resulting in 
excitation in the basal ganglia (specifically the putamen, globus pallidus, thalamus, 
subthalamic nucleus) [28], [149], and the cortical and subcortical areas [28] suggest 
centrally mediated changes. Improvements in overall motor function can have profound 
effects on daily activities. 
 The effect of exercise interventions on motor function as it applies to dynamic 
postural control is particularly important in PD as improvements in balance can lead to a 
decreased risk of falls [152]. Most studies using an exercise intervention assessing 
postural stability show significant improvements in balance measures from balance 
training when the training targets the specific movements tested in the outcome measures 
[153], [154]. Additionally, task-specific balance training improvements have shown to 
sustain up to six months post intervention [155]. Although it is encouraging that people 
with PD can improve dynamic postural stability with interventional training, these results 
demonstrate that motor skill learning abilities are still present in people with PD [152]. 
Less is known about the effects of exercise on centrally mediated changes in balance in 
PD. A few studies show improvements in postural stability with training not specifically 
targeting outcome measures, such as weighted treadmill walking, with improvements in 
the Berg Balance Scale [156] and improvements in the pull test portion of the UPDRS 
[157], while cycling training has shown improvements on the Berg Balance Scale [158]. 
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Improvements in balance measures resulting from cardiovascular exercise are promising; 
however, more objective outcome measures will strengthen the knowledge of how 
exercise impacts dynamic postural control.    
 Exercise interventions investigating changes in gait parameters range from 
treadmill training [158], [159], to dancing [160], [161]. Overall, most exercise 
interventions elicit some improvements in gait [160], [162]. Similar to balance training 
targeting improvements in postural stability measures, many interventions targeting 
improvements in gait measures are treadmill or walking based [162]–[164]. Other studies 
focusing on strength training experienced improvements in gait parameters [165], [166], 
which may be due to improvements in muscular function [167], [168]. High-intensity 
cycling training has shown improvements in gait measured by the Timed Up and Go test 
and increased gait speed [158], and although common gait measures have objective 
quantifiable results, such as time, distance, etc., tests like the Timed Up and Go test and 
6-minute walk test fail to describe quality of gait. A study by Mirek et al. used motion 
capture technology to characterize changes in gait in greater detail, such as joint ROM, 
due to exercise intervention [169]. Understanding methods to improve PD gait is crucial 
for decreasing fall risk; however, walking while mentally occupied further decreases gait 
function and poses a greater risk. Although there is a growing understanding of how 
exercise can improve gait in PD, there is little known of how exercise can affect gait 
under DT conditions.  
 People with PD experience increased gait deficits when performed simultaneously 
with a cognitive task [109]–[112], and efforts are being made to uncover interventions to 
improve DT abilities in PD [170]–[172]. Improvements in DT performance are often 
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elicited through DT training [173]; however, less is known on how interventions 
dissimilar from DT training affect gait under DT conditions. A study by Altmann et al. 
investigated how aerobic cycling exercise affects DT performance; however the motor 
portion of the DT test was cycling as well [171].  
In addition to effects on physical outcomes, exercise can also result in positive 
effects on cognitive function. A meta-analysis by Colcombe and Kramer concluded that 
aerobic exercise increases cognitive test performance across different cognitive tests, 
exercise programs, and participant characteristics. Of these results, executive control 
processes demonstrated the greatest improvements [174]. Additionally, studies have 
shown increases in brain mass in the prefrontal, temporal, and cortical regions as a 
response to aerobic exercise [175]. Following this trend, exercise interventions with a PD 
population involving moderate- to high-intensity aerobic exercise also exhibit cognitive 
improvements. Similar to Colcombe’s findings, the greatest improvements occurred in 
executive function tasks [139], [176], [177]. 
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CHAPTER II 
SPECIFIC AIMS, STUDY DESIGN AND PARTICIPANTS 
2.1 Specific Aims  
Aim 1: To determine the effects of an intensive aerobic cycling intervention on 
postural responses following an induced platform perturbation. This assessment was 
an application developed by Motek as part of a battery of assessments for patients with 
Parkinson’s disease. The “Time to Stability” application quantifies postural responses by 
measuring time and body mass excursion. The test begins with the participant standing in 
the center of the force plate with both feet firmly planted in a comfortable, narrow stance. 
The center of pressure is recorded by the system and stored. A series of platform shifts 
occur in four directions, at varying time intervals, and different accelerations. The 
direction and time interval are randomly programmed, and the acceleration remains 
constant for each test (three tests will be performed, one at each acceleration). Before 
each shift, the platform returns to center and a visual cue lets the participant know that 
the next platform shift is approaching.   
 Subjects completed this assessment once before beginning the exercise regimen to 
establish their “baseline” values, and once after completion. Baseline scores were 
compared to the post-exercise scores of each individual participant. 
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Aim 2: To determine the effect of an intensive aerobic cycling exercise on 
biomechanical gait parameters and cognition in ST and DT conditions. Three tasks 
were performed to evaluate ST and DT changes: a self-paced walking ST, three cognitive 
ST’s, and three walking/cognitive DT’s. Biomechanical gait parameters were quantified 
as walking speed, cadence, step length, joint angles, marker movement, and gait 
regularity. The verbal fluency test, the serial subtractions test, and the N-back test served 
to assess executive function, attention and working memory in the single tasks, as well as 
to increase cognitive loading in the DT conditions. All tests proceeded for 60 seconds.  
 Subjects completed the gait assessments once before beginning the exercise 
regimen to establish their baseline values, and once at the end of the intervention. 
Comparisons were made between baseline and post-exercise for ST and DT conditions to 
assess changes due to the exercise intervention, as well as between ST and DT conditions 
to assess changes due to DT cognitive loading. 
2.2 Subjects  
 Forty-five participants were recruited for this study, comprising three subject 
groups: PD intervention (PDE), PD non-intervention control (PDC), and healthy age-
matched control (HC). Forty-two subjects participated, 14 per group; one participant in 
the PDE dropped out due to physical inability to complete study tasks, one participant in 
the PDC group dropped out due to a broken shoulder, and one age-matched participant in 
the HC group was removed to equalize the groups. Participants were recruited from the 
CYCLE clinical trial (R01NS673717) in the Neural Motor Lab [178], and those who 
participated in past studies and indicated willingness to be contacted in the future. The 
intervention group included exercisers in both the forced and voluntary cycling groups, 
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and the PD non-intervention group included some individuals who have already 
completed the CYCLE Trial. Recruitment involved asking participants: if they were 
willing to be contacted about a concurrent additional study, a phone call follow-up 
involving educating the participant about this study, review of the consent form, and the 
researcher answering any and all questions. Age-matched healthy control subjects were 
recruited from the subjects with Parkinson’s. The Parkinson’s subjects (both intervention 
and non-intervention groups) were asked if they have a spouse, friend, family member, 
etc. in the same age range who may be interested in participating. The inclusion criteria 
for the healthy control participants are that they are within three years of age of the 
subject with whom they are matching, and must be able to stand unassisted. The 
exclusion criteria include: known neurological or balance disorders. The primary 
inclusion criteria included: clinical diagnosis of idiopathic Parkinson’s disease; between 
ages 30-75 Hoehn and Yahr stage II-III when on antiparkinsonian medication; not 
currently involved in formal exercise intervention or clinical study; ability to stand 
unassisted. The primary exclusion criteria included: existing cardiopulmonary disease or 
stroke; dementia; and any medical or musculoskeletal contraindications. The subject 
consort diagram is illustrated below (Figure 6), as well as baseline demographics (Table 
2) and a sample of outcome measures from the exercise intervention for the PDE group 
(Table 3). 
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Figure 6 – Subject consort diagram. PD, Parkinson’s disease; EOT, end of treatment. 
 
Table II – Subject baseline demographics 
Mean (SD)  PDE PDC HC 
Number of subjects 14 14 14 
Gender (male) 8 9 4 
Age (yrs) 64.9 (5.4) 62.2 (7.1) 64.0 (5.0) 
Leg Length (m) 0.83 (0.06) 0.83 (0.04) 0.80 (0.04) 
Weight (kg) 76.80 (20.89) 88.46 (20.01) 74.17 (15.04) 
Hoehn and Yahr 
stage 
2.2 (0.4) 2.2 (0.4)  
 
PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC, 
healthy control group. 
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Table III – Exercise intervention mean outcomes of PDE group  
Outcome variable  Mean (SD) 
# of sessions attended 23.71 (0.82) 
Heart rate during session (beats/min) 115.10 (14.63) 
HHR during exercise sessions (%) 69.50 (11.79) 
Cadence (revolutions per minute) 75.97 (13.01) 
 
HHR, % heart rate reserve. 
 
 Participants were off antiparkinsonian medication for this study. In addition to 
physical improvements due to medication, dyskinesia caused by levadopa has shown to 
result in decreased postural stability, exaggerated arm swing, and increased sway during 
stance phase [47]. Eliminating factors that alter the subjects physically increases the 
integrity of the measurements.  
2.3 Study Design  
Data collection for both Aim 1 and Aim 2 occurred during the same testing session. The 
order of data collection is illustrated below. Testing proceeded from top to bottom, tests 
aligned horizontally occurred in random order (see Figure 7)   
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Figure 7 – Order of testing session. Tasks listed vertically are in chronological order 
(beginning at top), tasks listed horizontally are randomized. 
 
The CYCLE trial intervention duration was eight weeks, with three exercise 
sessions per week (totally 24 exercise sessions). Participants completed a cardiovascular 
stress test prior to the start of their intervention to determine maximum heart rate reserve. 
Exercise sessions included a five-minute warm up, a 40-minute high-intensity exercise 
session, and a five-minute cool down. Subjects in the PDE group were comprised of 
exercisers in both the voluntary (self-paced cadence) and forced (bike-set cadence) 
exercise groups from the CYCLE trial. Despite differences in group assignment, all 
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exercisers were either programmed or encouraged to exercise at resistance and cadence to 
keep their heart rate in 60-80% of their heart rate reserve [178].  
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CHAPTER III 
DYNAMIC BALANCE RECOVERY 
3.1 Introduction 
Postural instability is one of the cardinal motor symptoms of PD [10]. Poor 
balance can increase fall risk, decrease balance confidence and lead to decreased physical 
activity [74]. Dynamic stability, particularly motor responses to perturbations, can be 
important in navigating daily balance challenges. Specifically, medium and long latency 
muscle responses, which participate in feedback loops associated with the cerebellum and 
basal ganglia [179], are impaired with PD, and take longer to initiate and process under 
balance destabilizations [62].  
 Physical training interventions aimed at improving postural stability in older 
adults can improve reactive recovery responses and reduce incidence of falls [180]. 
Various types of exercise and physical training have also proven beneficial in those with 
mild to moderate PD [136], [181]. Animal models have demonstrated changes in 
neurotropic factors post exercise along with PD symptom improvement [26], [27], [142], 
while human studies have shown improvements in UPDRS scores as a result of high-
intensity cycling [29], [30], [149]. The findings that dopaminergic therapy does not 
improve postural control [47] suggest that non-dopaminergic regions of the brain impact 
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dynamic postural stability [40] and support the exploration of treatments alternative to 
medication. This study aims to investigate if a high-intensity cycling intervention can 
elicit centrally mediated changes in the areas that affect improvements in dynamic 
balance.  
 Healthy individuals possess the ability to central-set, or prepare sensory and 
motor systems to react appropriately to an anticipated change in physical surroundings, 
such as a platform perturbation. This, in turn, can decrease the time spent in regaining 
balance [182]. This central-set ability is decreased in PD, and patients often lack the 
ability to appropriately scale their muscular responses to changing stimulation [68], 
[182]. This study aims to investigate how individuals with PD differ from healthy peers 
in their ability to scale motor responses, how quickly and accurately the responses are at 
regaining balance, and if exercise can improve these balance measures in people with PD. 
The time taken to regain balance and the center of pressure excursion represent the 
resultant physical movements of compensatory postural adjustments necessary to regain 
postural stability after a balance destabilization.   
3.2 Methods 
3.2.1 Testing Procedure 
The “Time to Stability” application, developed by Motek Medical, functions by 
destabilizing the subject, and measuring their postural response performance. 
Destabilization occurs via unexpected, horizontal displacement of the platform. The test 
measures the time taken to regain balance after destabilization, and center of mass 
displacement.  
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Prior to test initiation, the system calibrated the subject by estimating center of 
pressure (COP). Once successfully calibrated, the platform underwent a series of shifts, 
inducing a temporary loss of balance. After the subject reestablished postural stability 
and returned to their original, balanced position, the platform slowly returned to the 
center, neutral position and prepared for the next shift.    
Studies have demonstrated significant impairments with perturbation response 
scaling in Parkinson’s disease [62], [102], [183]. To assess differences among various 
difficulty levels, a total of three tests were performed (in random order), one at each 
acceleration level: 0.25 m/s2, 0.5 m/s2, and 1.0 m/s2.  At each level, eight shifts occurred, 
two in each direction: forward, backward, left and right. The platform displacement was 
the same for all shifts, at 0.081 meters. Upon the start of each shift, an orange circle 
appeared on the screen, warning the subject of the impending platform shift. After the 
appearance of the orange circle, the platform shifted after a random time delay between 
one and four seconds. The unknown direction and timing of the shifts intended to reduce 
anticipatory postural adjustments. The subject’s feet were separated by 5.0 cm to 
standardize the base of support between trials. A narrow base was chosen based on 
previous findings that a narrow stance results in a significant difference in center of mass 
displacement between people with Parkinson’s and controls, where no significant 
difference was seen in a wider stance [61]. 
Friedman’s ANOVA’s revealed no significant difference between shift directions 
within an acceleration level for any subject groups (p > 0.05), therefore all eight shifts 
were collapsed per acceleration level.   
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3.2.2 Instrumentation 
The Time to Stability application utilized various components of the CAREN 
system to provide testing conditions and for data collection. The forces exerted through 
the feet, measured from the force plate are used to estimate the center of pressure (COP). 
The platform, controlled by hydraulic motors, induced the perturbation shifts. Images 
projected on the surround screen provided a visual testing environment, and minimal 
visual cues. The D-Flow software orchestrated the functionality of the test, as well as 
collected and completed preliminary processing of the data. 
3.3 Data Analysis 
  The “Time to Stable” (TTS) outcome is the time in seconds from when the 
platform has reached its maximum displacement to when the estimated COP has reached 
“balanced”. During calibration, the average COP and standard deviation of the average 
COP is calculated. The subject is considered balanced when the standard deviation of the 
COP (measured in both the medial-lateral and anterior-posterior directions for 100 ms) is 
lower than the initially recorded measurement. The COP outcome measure is provided by 
the application in both the anterior/posterior and left/right directions as a coordinate 
value. The COP excursion (COPex) outcome measure is obtained from the COP data 
along both the anterior/posterior and left/right axes, and is collected over the same time 
frame as the TTS measure. Both TTS and COPex are reported as the average of the eight 
shifts performed within the same acceleration magnitude. 
The COPex is the 2-dimensional path of the COP during a perturbation shift, 
calculated using the ‘arclength’ Matlab function [184]. Prior to computing the path length 
of the 2-dimensional COP, noisy data was processed using a threshold and interpolation 
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method. The D-Flow software calculates the COP from each force plate individually, (left 
and right) and takes the weighted average of the two. Instances where one foot lifts off of 
the platform are not properly accounted for, and the lack of consistent contact force 
between the two standing feet could lead to mathematical calculations resulting in 
distances outside of the reasonable limits of stability. This process involves removing 
noise point by point based on the theoretical speed that the point is traveling. Based on 
previous studies measuring speed of COP [185]–[187], a maximum threshold of COP 
speed was set at 0.50 m/s. First, the 2-dimensional speed of each COP point is calculated 
by two data points in chronological order from the first point to the end of the trial. Upon 
each comparison, the second time point of a pair is removed if the speed is above the 
threshold, and replaced with the coordinates of the previous point. This process handles 
noise based on physical properties, while leaving the “true” COP data signal untouched. 
On average, < 10% of the data was removed/replaced using this method.    
Shapiro-Wilk normality testing revealed non-normally distributed data for over 
50% of the TTS data; therefore, nonparametric measures were used for all TTS data 
analysis. For baseline comparisons between groups, a Kruskal-Wallis ANOVA was 
performed. A Friedman’s ANOVA was used to determine the difference between shift 
levels (0.25 m/s, 0.5 m/s, 1.0 m/s) for baseline and, if applicable, EOT testing sessions of 
all subject groups. If significant differences were found, Wilcoxon Signed Ranks tests 
were used for pairwise comparison. Wilcoxon Signed Ranks tests were also used to 
compare baseline to EOT of outcome measures. To test for differences due to the 
exercise intervention, the ΔTTS was calculated (EOT – baseline) and compared between 
the PDE and PDC groups for each acceleration level using Mann-Whitney U tests.  
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The results of Shapiro-Wilk normality testing of the COPex data revealed normal 
distribution; therefore, one-way, two-way, and two-way repeated measures ANVOA’s 
were used for COPex analysis. Where significance was found, pairwise comparisons with 
Bonferroni corrections were completed. For baseline comparisons between groups a two-
way ANOVA comparing factors of group (PDE, PDC, HC) and acceleration level was 
used. A two-way repeated measures ANOVA investigating the factors of session 
(baseline and EOT) and acceleration level was completed for both PDE and PDC groups. 
Due to unforeseen loss of data, COPex data analysis included the PDE group: N = 12, the 
PDC group: N = 6, and the HC group: N = 7.  
3.4 Results 
3.4.1 Time Taken to Regain Balance 
 Comparing baseline measures between the PDE, PDC and HC groups, no 
significant differences were found for time taken to regain balance for all three levels of 
acceleration. Differences in TTS across the three acceleration levels were compared for 
each group, as well as each testing session (baseline and EOT for PDE and PDC, baseline 
only for HC). The PDE group at baseline showed significant differences between 
accelerations: the median TTS during the 0.5 m/s acceleration was 50.7% longer than the 
0.25 m/s acceleration (Z = -2.57, p < 0.05); and the median TTS during the 1.0 m/s 
acceleration was 41.4% longer than the 0.25 m/s acceleration (Z = -2.76, p < 0.01); and at 
EOT the 1.0 m/s median acceleration experienced a 26.0% longer TTS than the 0.25 m/s 
acceleration (Z = -2.57, p < 0.05). The PDC group at baseline showed that the median 
TTS at the 1.0 m/s acceleration was 40.5% longer than the 0.25 m/s acceleration level (Z 
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= -2.39, p <0.05), and there were no significant differences between acceleration levels at 
EOT. For the HC group, the 3 accelerations levels were not significantly different.  
 Significant differences in TTS comparing baseline to EOT testing sessions are 
seen in the PDE group with the 0.5 m/s median acceleration decreasing by 22.1% (Z = 
2.76, p < 0.01). The PDC group did not show any significant difference in TTS from 
baseline to EOT for any acceleration level. In comparing the ΔTTS between the PDE and 
PDC groups, no significant differences were found at any acceleration level (see Figure 
8). Results listed in Appendix A.  
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Figure 8 – Time to Stable median results in seconds for all three subject groups. PDE, 
Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC, healthy 
control group; EOT, end of treatment. Square inside 25%-75% box indicates mean. 
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3.4.2 Center of Pressure Excursion  
 At baseline, there was a significant main effect of group; the mean COPex for the 
HC group was 16.6% larger than the PDC group (t = 2.86, p < 0.05). There was no effect 
of level or interaction at baseline. The two-way repeated measures ANOVA for the PDE 
group revealed a significant main effect for the testing session, F(1, 11) = 7.91, p < 0.05, 
such that the average COPex during EOT testing decreased significantly from baseline 
testing by 0.17 meters (SD = 0.05). The main effect of acceleration level was non-
significant, nor was the interaction effect. The two-way repeated measures ANOVA for 
the PDC group yielded no significant main effects for testing session, acceleration level, 
or their interaction effect (see Figure 9). Results listed in Appendix B.  
Figure 9 – Center of Pressure Excursion mean results in meters, for each acceleration 
level (m/s2). PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control 
group; EOT, end of treatment. 
 
 
3.5 Discussion 
  Both PD groups did not differ from the HC group on time taken to regain balance 
for any of the three acceleration levels. Contrary to previous studies [104], [188], there 
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modify perturbation recovery time to different acceleration levels. The PDE and PDE 
groups had significant differences in TTS in one or two levels at baseline, which differs 
from the hypothesis that the PD groups would be less able to scale their recovery time 
responses than the HC group, and would take similar amounts of time for all three 
different accelerations. The results of this study did not demonstrate a lack of scaling of 
postural responses in a PD population as anticipated; however, these results are similar to 
other studies which have shown intact or partial gain scaling, but decreased amplitude 
[104], [107]. Studies that have demonstrated significantly slower perturbation responses 
and decreased ability to scale postural responses compared to controls had PD patient 
populations with greater disease severity, suggesting that disease severity may contribute 
to degree of dynamic stability deficits [61], [105]. Additionally, Schieppati and Nardone 
have found that PD patients with mild impairment show similar muscle activation 
patterns compared with age-matched healthy controls [62], and Dimitrova, Horak and 
Nutt found that muscle coactivation in response to a perturbation significantly correlated 
with disease severity (subjects ranging from 1-4 on Hoehn and Yahr scale) [60].  
 The time taken to regain a balanced position, measured here as TTS, represents 
the time taken for motor responses to adequately stabilize the body. This process involves 
muscle responses from both cortical and subcortical activation with variable activation 
latencies, [60], [68], [98], [99], [182], and may not be well characterized by time alone. 
The movement of the COP may provide additional information on how the body 
responds to perturbations.  
 Although numerous balance deficits in PD are well established, center of pressure 
excursion specifically has not been well studied in the PD population. The results of this 
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study indicate no significant differences between the COPex of mild to moderately 
impaired individuals with PD (for the PDE group) and healthy older adults, which 
mirrors the findings of a similar study [189]. Although there was a significant difference 
between the PDC group and HC at baseline, there was no significant difference between 
the PDE and PDC groups. Therefore, further analysis proceeded as intended.  
 Comparing the results of the PDE and PDC groups of this study, the PDE group 
shows a significant decrease in COPex, whereas the PDC group has no significant 
change. Previous studies demonstrate that higher COP excursion indicates worse 
functional balance [187], [190], [191], therefore suggesting improvement in the PDE 
group. Although interventions employing physical activities which practice a balance 
component have shown efficacy in improving postural stability in a PD population [180], 
[181], anti-Parkinson’s medications have not shown consistent improvements in balance 
deficits [47], [68]. Impaired acetylcholine signaling pathways related to postural control 
can be damaged by Lewy body aggregation, adding to the complexity of PD balance 
impairment, and perhaps explaining the lack of improvement from medication [40]. 
Furthermore, potential improvements in dynamic balance resulting from an exercise 
intervention not only demonstrates the ability of people with PD to improve their balance 
from a task that does not practice balance, but it also suggests that exercise may elicit 
changes differently than the levodopa-replacing mechanism of medication.   
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CHAPTER IV 
GAIT AND DUAL-TASK 
4.1 Introduction  
 In healthy individuals, neural coupling controls the cyclical movement of arm 
swing and leg movements during walking gait, and is likely controlled by central pattern 
generators [192]. The integration of spinal cord output and higher level executive 
processes results in successful gait performance [192]. These neural circuits are disrupted 
in PD [33], resulting in gait impairments such as stooped posture, decreased speed, 
reduced arm swing, reduced stride length, decreases in joint ROM, [14], yet no difference 
in cadence (steps per minute) [11], [13], [15], [16], [19]. Gait stabilizing tactics also 
common to PD gait include increased double leg support time [12], [16], [17], [20] and 
decreased swing phase [16], [44]. The magnitude of gait impairment is typically inversely 
correlated with disease severity [11].   
Gait deficits present in PD are further exacerbated under DT conditions. 
Decreases in task performance occur when two tasks are performed simultaneously in a 
healthy population; however, those with PD generally exhibit greater dual-task costs than 
healthy peers [109]–[112]. Under DT conditions people with PD may experience the 
following: increased gait asymmetry; slower; shorter steps; increased double support time 
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[113], differences in gait profile and variability in pelvic tilt, pelvic obliquity, pelvic 
rotation, hip flexion/extension, hip abduction/adduction, knee flexion/extension, and 
ankle dorsi/planar flexion [114].  
People with PD also experience non-motor symptoms, such as cognitive decline. 
The basal ganglia-thalamo-cortical circuits that cause motor declines when affected by 
PD have parallel associative/cognitive functions [33]. The impact of PD on executive 
function results in declines that are detectible in neuropsychological tests such as logical 
memory and associative learning [84]. Cognitive and motor declines are exacerbated 
under DT conditions when attentional demands are increased and adequate neural 
compensation is not available [119]. 
Disease modifying treatments are not yet available for PD, but dopaminergic 
medication and deep brain stimulation provide symptom relief  [3], [24]. Unfortunately, 
side effects such as dyskinesia (involuntary movements) [3], and risks of invasive surgery 
[24] are associated with these treatment options. High-intensity aerobic exercise targets 
neurological modifications to alleviate symptoms as well; however, it is associated with 
lower risk and potentially positive side effects.  
Parkinson’s disease patients with relatively more severe gait declines show higher 
prefrontal activation during gait tasks than PD patients with relatively milder gait 
declines. This suggests compensatory neural activation to improve gait performance 
[193]. Exercise studies have shown increases in volume in the prefrontal, temporal, and 
cortex regions as a response to aerobic exercise, [175], suggesting that exercise may have 
a direct effect on areas of the brain that affect gait function in PD. Studies investigating 
cycling exercise and PD measured motor symptom outcomes [28]–[30], [150], and brain 
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activation [28], with key findings related to motor function including 35% UPDRS 
improvement at end of trial and improvements in upper extremity function (measured as 
grasping forces and tremor). Exercising the lower extremity, while experiencing 
improvements in symptoms of limbs not involved in the exercise suggest that the cycling 
intervention facilitates neurophysiological changes directly impacting PD symptoms 
[28]–[30], [150].  
Exercise studies have also shown improvements in cognitive function, with the 
greatest improvements in executive control processes [174]. These improvements have 
also been found in PD with moderate to high-intensity aerobic exercise, and similar to 
Colcombe and Kramer’s findings, the greatest improvements occurred in tasks involving 
executive function [139], [176], [177]. 
Studies have shown significant improvement in gait function after an exercise 
intervention [158], [159], [194]; however, individuals frequently encounter walking 
conditions that are more complicated than the ST conditions commonly tested in clinical 
environments. When an individual is walking while talking on the phone, answering a 
question, recalling the directions to their desired location, etc., they are effectively 
completing a cognitive-motor DT. Studies targeting DT performance improvement often 
employ physical interventions based on DT movements and exercises [195]. Whether the 
neurological effects of high-intensity exercise can affect DT performance in PD remains 
unclear. In addition to lower extremity outcome measures illustrating changes in gait, it 
has been suggested that arm swing may also serve as a proxy for gait function [115]. 
Research has shown that dopaminergic treatment has the ability to improve gait function, 
 49 
 
specifically arm swing [59]. However, it is unclear how a high-intensity exercise 
intervention can improve gait function illustrated by arm swing.  
This study aims to investigate the effect of a high-intensity cycling exercise 
intervention with a PD population on gait parameters under ST and DT conditions. The 
various biomechanical outcomes measured with a motion capture system will provide an 
objective summary of changes in PD gait under different task conditions, and after 
intervention.  
4.2 Methods 
4.2.1 Testing Procedure 
 Participants completed ST and DT testing on the platform in the CAREN 
environment. The ST tests were completed first, with the participant seated on a chair 
with the test prompts delivered visually on the screen. After all three cognitive ST tests 
were complete, the participants walked on the treadmill for 60 seconds for the motor ST 
test. Next, the DT tasks were performed, where the participant completed both the 
cognitive and motor tasks simultaneously. The versions of the cognitive tasks were 
different for each testing presentation to minimize learning effect.  
 Walking speed was self-selected by the participants using the self-paced feature 
of the CAREN system. The “self-paced” speed algorithm uses the four anterior/posterior 
iliac crest markers of the pelvis to adjust the treadmill speed to the pace of the individual 
relative to their positon on the treadmill. Once the participants audibly declared their 
speed “comfortable” and “constant”, that speed was recorded and manually entered for 
all walking trials in that testing session. The speed was held constant for the ST and DT 
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trials in the same session to minimize the confounding effect of speed on other gait 
parameters that may change due to DT effects.  
4.2.2 Instrumentation 
 The application used for providing testing conditions as well as collecting and 
completing preliminary data processing was custom built in the D-Flow software. In 
addition to the hardware of the CAREN system used to create the testing environment 
and data collection, the HBM with its specific marker model and the Gait Offline 
Analysis Tool were used for initial data processing.   
4.2.2.1 Software - Human Body Model 
 The Human Body Model (HBM) developed by Motek Medical uses marker and 
force plate data to estimate subjects’ kinematics. The model has 18 body segments and 46 
degrees of freedom, with the pelvis serving as the root segment. Although complex, this 
process computes with sufficient speed to function in real-time, while the subject is on 
the system (Figure 10). The first step involves calibrating the model to the subject. The 
initialization uses the marker coordinates, marker diameter, and knee and ankle width to 
calculate joint centers, bone lengths and joint axes. The subject weight and gender are 
used to calculate the mass properties of the model. Data extraction and body segment 
compilation use reference frames, defined during the initialization pose, illustrated below 
(Figure 11). Generally, the origin of each segment lies at the proximal joint, and the Z 
axis is oriented to go through the distal joint, in accordance with de Leva [1].  
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Figure 10 – Data processing through the Human Body Model (HBM) [1].  
 
Formulas unique to each joint, and anatomical information available from 
surrounding markers are used to calculate the joint centers. The coordinate system for 
HBM is: X=anterior; Y=left; Z=up. The hip joint center, for example, uses an algorithm 
presented by Bell at al. [196]: 
- X of hip joint center is X of greater trochanter marker 
 - D is distance between LASIS and RASIS 
 - Y of right hip joint center is Y of RASIS + 0.14D (- 0.14D for left) in the local  
  Y direction  
 - Z of hip joint center is Z of ASIS – 0.3D 
Mass properties of body segments are calculated using anatomical information from de 
Leva’s anthropometry model, which provides segment mass as a percentage of total body 
mass, segment center of mass as a percentage of segment length, and radii of gyration for 
frontal plane, sagittal plane, and longitudinal axis [197].  
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 The joint axes and degrees of freedom are based on International Society of 
Biomechanics standards [134], [198], [199]. The joint rotation sequence, (described 
earlier) follows the pattern of the axis with major muscle movement first, then the lesser 
two axes. For example, with the pelvis coordinate system as Z=yaw, Y=pitch, X=roll, the 
knee rotation sequence follows: Y (flexion), X (abduction), Z (internal rotation).  
 Once the program acquires all of the necessary input information, the HBM is fit 
to the subject. The model is scaled to the size of the subject, and forward kinematic 
equations are used to calculate the coordinates of the markers. The skeleton pose is then 
found by a process known as global optimization [200], where the entire model as a 
whole is best fit to the markers. This function is a nonlinear least-squares equation, which 
essentially minimizes the difference between the measured marker pose and the desired 
pose of the model. This is an iterative solution process, where the function runs 
repeatedly until the solution with the smallest difference is found. Since this process 
occurs for each frame, the computation occurs quickly, at the speed of 1.0ms to run in 
real-time [130]. 
 An important factor in every calculation is filtering. Since the raw data undergoes 
many calculations, unfiltered noise will become amplified through the process. A second-
order Butterworth filter, for both force plate and marker data is used. Since filtering 
causes a time delay, choosing the appropriate filter was a balance between power and 
speed to allow for continual real time processing [130]. 
4.2.2.2 Marker Model 
 This study used the full-body marker model, which uses 47 markers to discern the 
body segments and the kinematic degrees of freedom (see Figure 11 and Table IV). The 
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goal for a good marker model is to use the least amount of markers while providing the 
cameras with enough information to accurately assign the location of each body segment. 
Three markers are the minimum for each body segment to properly discern the x, y, and z 
coordinates. This eliminates the possibility of two markers rotating about an axis that 
produces no translation, therefore appearing to have no motion. It is also advantageous to 
have markers that may apply to more than one segment to minimize the total number of 
markers. For example, the lateral epicondyle is part of both the femur and shank 
segments [1].  
 
Figure 11 – Full-body marker model [1].  
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Table IV – Anatomical marker placement key [1]   
 
 
4.2.2.3 Outcome Variables 
 The CAREN lab provides vast amounts of data from its different integrated 
systems. The Vicon motion capture system yields marker coordinates in an x, y, z 
coordinate system, the forces and moments in the x, y, and z directions, and the video 
cameras record video from two different angles. These inputs are all integrated into the 
D-Flow software, which can take the raw data and compile more meaningful metrics for 
various applications. In addition to D-Flow, the CAREN system is equipped with the Gait 
Offline Analysis Tool, which manipulates saved data from an HBM session for further 
Marker 
Name 
Anatomical Marker Location Marker 
Name 
Anatomical Marker Location 
LASIS Left anterior superior iliac spine THEAD Top of head 
RASIS Right anterior superior iliac spine RHEAD Right side of head 
LPSIS Left posterior superior iliac spine LHEAD Left side of head 
RPSIS Right posterior superior iliac spine SACR Sacrum 
LGTRO Left greater trochanter T10 Vertebra T10 
RGTRO Right greater trochanter NAVE Navel 
LLEK Left lateral epicondyle of knee STRN Sternum 
RLEK Right lateral epicondyle of knee LDELT Left deltoid of the humerus 
LLM Left lateral malleolus  RDELT Right deltoid of the humerus 
RLM  Right lateral malleolus LFIN Left 3rd metacarpal  
LTOE Left head of first toe RFIN Right 3rd metacarpal 
RTOE Right head of first toe BBAC Center of right scapula 
LSHO Left acromion process of shoulder  FLTHI Left mid-thigh 
RSHO Right acromion process of 
shoulder 
FRTHI Right lateral mid-thigh 
LLEE Left lateral epicondyle of elbow LATI Left lateral tibialis anterior 
RLEE Right lateral epicondyle of elbow RATI Right lateral tibialis anterior 
LMEE Left medial epicondyle of elbow LHEE Left posterior of heel 
RMEE Right medial epicondyle of elbow RHEE Right posterior of heel 
LLW Left lateral epicondyle of wrist LMT5 Left head of 5th metatarsal 
RLW Right lateral epicondyle of wrist RMT5 Right head of 5th metatarsal 
LMW Left medial wrist LFRM Left mid forearm 
RMW Right medial wrist RFRM Right mid forearm 
XYPH Xyphoid process FHEAD Forehead  
C7 Vertebra C7   
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analysis. The metrics exported from the Gait Offline Analysis Tool include: marker 
coordinates, joint angles, stance phase, stride length and treadmill speed. This data was 
further processed, if necessary, and organized with a custom Matlab program to yield the 
biomechanical outcome variables listed below in Table V. 
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Table V – Biomechanical outcome measures 
 
Variable  Description 
Speed Measured by self-selected speed algorithm 
Cadence Number of heel strikes per minute (both left and right) 
Step Length Meters from heel strike to subsequent heel strike on each leg 
separately 
Stance Phase Percent of gait cycle (defined as heel strike to subsequent heel 
strike on same leg) in which the foot makes contact with the 
ground. The remainder of the cycle is considered swing phase 
Ankle ROM Ankle flexion/extension (plantar flexion/dorsiflexion) along 
the X axis in the sagittal plane, measured as maximum 
flexion minus minimum flexion per gait cycle 
Knee ROM Knee flexion/extension, along the X axis in the sagittal plane, 
measured as maximum flexion minus minimum flexion per 
gait cycle 
Hip ROM Hip flexion/extension, along the X axis in the sagittal plane, 
measured as maximum flexion minus minimum flexion per 
gait cycle   
Arm swing path length The 3-dimensional path length per arm swing cycle, which is 
measured from the maximum anterior position in the –Z 
direction to the subsequent maximum anterior position of the 
finger marker, which is placed approximately in the center of 
the back of the hand 
Normalized Jerk Jerk is calculated from the arm swing path length per arm 
swing cycle (defined above), normalized by time and distance 
Trunk Rotation ROM Rotation about the Y axis in the transverse plane, left twist is 
a positive value, right twist is negative, measured as 
maximum rotation value minus the minimum rotation value 
per gait cycle 
Pelvic Tilt ROM Rotation about the X axis in the sagittal plane, anterior tilt 
(ASIS markers lower than PSIS markers) is a positive value, 
posterior tilt (PSIS markers lower than ASIS markers) is a 
negative value, measured as maximum rotation value minus 
the minimum rotation value per gait cycle 
Pelvic Obliquity ROM Rotation about the Z axis, in the frontal plane. Left drop/right 
lift is a positive value, left lift/right drop is negative. 
Measured as maximum angle minus minimum angle per gait 
cycle 
Pelvic rotation ROM Measured similarly to trunk rotation 
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4.2.3 Cognitive Tasks 
4.2.3.1 N-Back 
 The N-back task is a working memory test where a list of stimuli is presented at 
regular intervals, and the participant is asked to recall the stimulus presented N times 
prior in the list [201]. This test has been used in various populations, for various purposes 
[201]–[204]. Commonly seen versions include a string of numbers, shapes, or an object 
placement in space [205]. For this study, the 2-back version of the test was used, which 
entails the subject to recall whether the letter currently presented is the same (“yes”) or 
different (“no”) from the letter presented two prior in the string. The score is calculated as 
number of correct responses.  
4.2.3.2 Serial Subtractions 
 The serial sevens subtractions test was first developed in 1942 by Dr. Max 
Hayman M.D. as a time efficient and cost effective cognitive test to assess mental 
capacity of cognitively challenged populations. The original design of the test consists of 
starting with the number 100, subtracting seven, subtracting seven from the calculated 
difference, and continually repeating these subtractions until the number two is reached. 
The score is the completion time, as well as the number of correct answers over the 
number of total answers [206]. This test uses working memory and information 
processing, which are both related to executive functioning [11]. Modifications are often 
made to the test, such as using a different starting number [108], different subtrahend 
[108], [116], allowing a limited time for test completion [108], or scoring by counting 
total number correct [109]. This study used a version of this test where a random starting 
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number between 200 and 400 was used, and calculations subtracting seven occurred for 
60 seconds. The number of correct responses only was used to calculate the score.  
4.2.3.3 Verbal Fluency 
 The verbal fluency test entails producing as many words as one can think of in a 
specific category in a set time frame. Versions of the test vary by category, such as 
“animals”, “colors”, or “words that begin with the letter F”, and response, written or oral. 
The test is scored as number of correct, unique answers in one minute (oral) or five 
minutes (written) [86]. The verbal fluency test examines the executive function of 
selective attention, internal response generation and self-monitoring [207]. The 
Controlled Word Association Test (COWAT) is a common, standardized version of 
verbal fluency. Three letters are given to the participant, allowed 60 seconds of response 
time per letter, and the score is combined from all three letter responses. Currently, there 
are two sets of letters that are considered equivalent and utilized in the COWAT [86]. 
Borkowski et al. have studied each letter of the alphabet individually to find equivalency 
in terms of possible answers [208], which broadens testing options. The letters S, T, F, 
and P were used for this study.  
4.3 Data Analysis 
 The spatiotemporal gait parameters compared between the PDE and PDC groups 
include: walking speed (m/s), cadence (steps/min), normalized step length (% of leg 
length) and stance phase (% of gait cycle). The kinematic gait parameters include: ankle, 
knee and hip ROM (degrees), ROM of trunk rotation in the transverse plane (trunk 
rotation) (degrees) and ROM of the pelvis in the sagittal, frontal, transverse and planes 
(pelvic tilt, pelvic obliquity, pelvic rotation) (degrees). The upper extremity gait 
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parameters include: normalized arm swing path length (PL) (% of arm length), and 
normalized jerk (NJ). Walking speed was selected at the beginning of each testing 
session, and remained constant for the remainder of the session across all walking and 
DT conditions. Cadence, step length, stance phase, and joint ROM were all calculated 
and reported through the Gait Offline Analysis Tool. A custom-built Matlab program 
provided additional data processing. Cadence was calculated by total number of steps 
taken for both feet combined, divided by the total time. Step length and stance phase 
were calculated per gait cycle, then the average was taken over all gait cycles completed 
per trial. Joint ROM was calculated from the joint angles reported per time stamp by 
finding the maximum and minimum angles per gait cycle to calculate the total ROM, and 
taking the average ROM over all gait cycles per trial. Further description of 
biomechanical outcome measures can be found in Table K.  
 Arm swing outcomes (PL and NJ) used 3-dimensional coordinate position data.  
First, the arm swing was calculated relative to the pelvis to account for body 
displacement within the motion capture volume. The pelvis center was found by taking 
the average of the 3-dimensional coordinates of the four iliac crest markers, which was 
then subtracted from the lateral wrist markers. The arm swing metrics were reported as 
average per arm swing cycle (one cycle defined as the maximum anterior position to the 
subsequent maximum anterior position). Path length computed from the left and right 
wrist markers using the ‘arclength’ Matlab function [184], describes the 3-dimensional 
distance traveled per arm swing. Path length was also used to calculate jerk, a measure to 
describe smoothness of movement.  
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Jerk, or smoothness of movement, is defined as the rate of change in acceleration. 
The methods for calculating arm swing jerk have been publish in previous work [115]. 
Using position data, the third derivative was taken to obtain jerk. Mathematical noise 
increases with each derivative calculation [209]; therefore, a jerk measurement derived 
from position data would be noisier from a jerk measurement derived from accelerometer 
data. To assess this discrepancy, trials were completed on the CAREN system to compare 
accelerometer-derived jerk and position-data-derived jerk. An individual walked at a 
constant speed with an iPod attached to the wrist, with a marker attached to the iPod 
itself. The jerk calculated from the position data was compared to the jerk calculated 
from the acceleration data from the iPod.  
 Before comparison, the appropriate filtration was found for both the 
accelerometer and position data. The accelerometer data from the iPod was filtered using 
a second-order Butterworth filter. The cutoff frequency was found using residual analysis 
[2]. This process involves comparing the difference between the raw and filtered signal, 
called the residual, across a range of cutoff frequencies. The residual is calculated as 
follows (N = number of sample points in time, 𝑥𝑖  = raw data at ith sample, 𝑥?̂? = filtered 
data at ith sample, see Figure 12): 
 
𝑅(𝑓𝑐) =  √
1
𝑁
∑ (𝑥𝑖 − 𝑥?̂?)2
𝑁
𝑖=1   [2] 
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Figure 12 – Residual analysis [Winter 1990], along the y-axis is the residual R(fc) 
calculated from increasing cutoff values (fc, along the x-axis), line de = estimate of noise 
residual, line bc = estimate of noise distortion and allowed noise, point a = projection of 
tangent line from line de at 0Hz , horizontal projection from point a to the residual curve 
creates point b, vertical projection of point b lands at the desired cutoff frequency, f1c.  
 
Once the appropriate filter was applied to the accelerometer data, the derivative 
was taken to obtain the jerk measure from the accelerometer data (accelerometer-to-jerk). 
Next, second-order Butterworth filters with a range of cutoff frequencies were applied to 
the position data, then the third derivative was taken (position-to-jerk): 
 
𝑓𝑖
′′′ ≈
𝑓1+2 − 2𝑓𝑖+1 + 2𝑓𝑖−1 − 𝑓𝑖−2
2ℎ3
 
 
The results of varying cutoff frequencies of the position-to-jerk data were then 
compared to the accelerometer-to-jerk data. Jerk by time plots were visually inspected, as 
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well as resulting values (see Figure 13). Keeping to the closest multiple of 0.05 Hz, a 
frequency cutoff value of 1.25 Hz was selected. 
 
Figure 13 – Comparing arm swing jerk plots between accelerometer derived and position 
derived data in anterior-posterior (z) direction. A: accelerometer derived jerk plot, B: 
position data derived jerk without additional filter, C: position data derived jerk with 2nd 
order Butterworth filter using 1.25 Hz cutoff frequency.  
 
Jerk can be employed and reported in a variety of ways [210], depending on the 
application. For this study, normalized jerk (NJ) was chosen [211] to account for the 
variability between subjects’ arm movements (T = total time, L = total length). 
A B 
C 
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𝑁𝐽 = 0.5 ∫ [𝑥(𝑡)2 + 𝑦(𝑡)2 + 𝑧(𝑡)2]
𝑡2
𝑡1
𝑑𝑡(
𝑇5
𝐿2
) 
  
All outcome measures were calculated for the left and right side separately, and 
further categorized into the more and less affected side based on severity of symptom 
presentation determined by UPDRS scores or self-report. Due to the lack of significant 
differences between the more and less affected sides, results were collapsed across sides. 
To test group differences at baseline, each outcome measure during the ST condition was 
compared between the PDE, PDC and HC groups. Kruskal-Wallis ANOVA was 
performed between the three subject groups, and Mann-Whitney U tests were performed 
between the PDE and PDC groups, and the PDE and HC groups.   
To assess differences in change over time/intervention, the delta (Δ = EOT – 
baseline) was computed for all outcome measures (PDE and PDC groups only), and 
compared between the PDE and PDC groups to assess changes due to the exercise 
intervention. Shapiro-Wilk normality tests revealed non-normality for over 50% of Δ 
outcome data, therefore Mann-Whitney tests were conducted for each Δ outcome 
measure, for each task condition (ST, BACK, SUB, VERB) between the PDE and PDC 
groups. Comparison between the PDE group at baseline and the HC group, and the PDE 
group at EOT and the HC group were completed using Mann-Whitney tests.  
 Cognitive test scores were analyzed for changes in cognition (Δ under ST 
conditions) and changes due to dual-tasking. In efforts to use cognitive test scores in the 
manner that clinicians do to assess cognitive changes [212], dual-task difference (DTD) 
was used. Dual-task difference is simply the raw change in score from ST to DT 
conditions. Changes due to dual-tasking were also analyzed for all gait outcome measures 
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for both the PDE and PDC groups. Friedman’s ANOVA’s were performed first between 
all four tasks (ST and DT’s) in a testing session, and if significance was found, 
subsequent pairwise Wilcoxon Signed Rank Tests were performed between the ST and 
each DT condition. The significance level was set at α=0.05. All statistical analysis was 
performed using OriginPro 2017 statistical software (OriginLab Corporation, 
Northampton, Massachusetts). Due to data integrity standards, some outcome measures 
have a decreased sample size. Particular outcomes that were deemed inaccurate and 
unrecoverable were omitted. Sample size for each outcome measure is listed in  
Appendix C.    
4.4 Results 
 Comparing the PDE and PDC groups at baseline and the HC group, there were 
significant differences in speed, stance phase, step length, hip ROM, PL, and pelvic 
obliquity ROM under ST conditions. 
Subsequent comparisons of the PDE and PDC groups showed no significant 
differences at baseline in any outcome measure under ST conditions.  
4.4.1 Change from baseline to EOT (Δ) 
 Of the spatiotemporal measures, significant differences in the change from 
baseline to EOT between the PDE and PDC groups existed for all measures. Results are 
listed in Appendix D. The change in self-selected walking speed from baseline to EOT in 
the PDE group (median = 0.11 m/s) was significantly greater than the Δ walking speed 
for the PDC group (median = -0.05 m/s), U = 146.5, p < 0.05 (See Figure 14). The Δ 
cadence was only significant for the ST condition, with a significantly larger increase for 
the PDE group (median = 4.52 steps/min) compared to the PDC group (median = -3.00 
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steps/min), U = 142, p < 0.05. The Δ stance phase was significant for the ST, SUB and 
VERB conditions, with the PDE group showing significant decreases compared to the 
PDC, and Δ step length showed significant increases for the PDE group compared to the 
PDC group for all task conditions. Of the lower extremity kinematic measures, there were 
significant differences in the change from baseline to EOT between the PDE and PDC 
groups for the ankle, knee and hip joint ROM (See Figure 15). The Δ ankle ROM for the 
BACK condition was significantly larger for the PDE group (median = 1.52) compared to 
the PDC group (median = -2.13), U = 153, p < 0.05. The Δ knee ROM was significantly 
larger than the PDC group for both the BACK and SUB conditions, and the Δ hip was 
significantly larger than the PDC group for all task conditions. Of the trunk and pelvis 
ROM measures, only Δ trunk rotation ROM showed significance, with the PDE group 
(median = 1.35) resulting in a significantly larger increase than the PDC group (median = 
-0.16), U = 135, p < 0.05. Of the arm swing measures, no significant differences were 
observed in changes in PL; however, the Δ NJ was significantly larger for the PDE group 
compared to the PDC group for the ST, BACK and SUB conditions (See Figure 15).         
 
Figure 14 – Average speed for Parkinson’s disease exercise (PDE) and Parkinson’s 
disease control (PDC) groups at baseline and EOT.   
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Figure 15 – Median results of change from baseline to end of trial (Δ) for lower 
extremity measures comparing Parkinson’s disease exercise (PDE) and Parkinson’s 
disease control (PDC) groups. ST, single-task; BACK, N-back dual-task; SUB, serial-7 
subtraction dual-task; VERB, verbal fluency dual-task; *, significant difference between 
PDE and PDC groups at p < 0.05 level. 
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Figure 16 – A) Results of change from baseline to end of trial (Δ) for normalized path 
length (PL), B) median results of change from baseline to end of trial (Δ) for normalized 
jerk (NJ). PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control 
group; ST, single-task; BACK, N-back dual-task; SUB, serial-7 subtraction dual-task; 
VERB, verbal fluency dual-task; *, significant difference between PDE and PDC groups 
at p < 0.05 level.  
 
4.4.2 Comparison between PDE and HC 
 Comparison between PDE at baseline and the HC group showed that the PDE 
group displayed significant gait deficits in speed, cadence, stance phase, step length, knee 
ROM, pelvic obliquity ROM, pelvic rotation ROM, PL and NJ. When comparing the 
PDE group at EOT with the HC group, the PDE group maintained gait deficits in pelvic 
obliquity ROM, PL and NJ, but was no longer significantly different in speed, cadence, 
stance phase, step length, knee ROM and pelvic rotation ROM (see Figure 17). Results 
listed in Appendix E. 
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Figure 17 – Median results for comparison between the Parkinson’s disease exercise 
group (PDE) and healthy control (HC) group. ST, single-task; BACK, N-back dual-task; 
SUB, serial-7 subtraction dual-task; VERB, verbal fluency dual-task; *, significant 
difference between PDE and HC groups at p < 0.05 level. 
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4.4.3 Change in Variability 
There were no significant differences between the PDE and PDC groups in Δ 
variability for any outcome measure.  
4.4.4 Cognitive Test Scores 
 There were no significant differences between the PDE and PDC groups in Δ 
under ST conditions for any of the cognitive tasks. 
4.4.5 Changes from ST to DT 
 Differences in outcome measures between ST and DT conditions were present for 
both the PDE and PDC groups. The PDE group experienced DT declines in cadence, 
knee ROM and pelvic tilt ROM. The PDC group experienced DT changes in cadence, hip 
ROM, PL, trunk rotation ROM, pelvic tilt ROM, and pelvic obliquity ROM, results listed 
in Appendix F. 
4.5 Discussion  
 As anticipated, significant differences were observed between all three subject 
groups. Subsequent group comparisons between the PDE and PDC groups resulted in an 
overall lack of significance between the two groups, and comparisons between the PDE 
and HC groups resulted in significant differences, with the PDE group showing gait 
declines across most outcome measures. These results are consistent with previous 
studies [17], [46], [213]. 
 To investigate changes in gait parameters in PD due to a high-intensity cycling 
intervention compared to changes observed in PD over the same time frame without a 
prescribed intervention, the Δ was compared between the PDE and PDC groups. The 
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comparison of the Δ for PDE and PDC groups was intended to account for inter-subject 
variability and possible improvements due to learning effects. However, in this particular 
sample group, the PDC group showed no significant change from baseline to EOT.   
 Not only did the self-selected speed increase significantly for the PDE group 
compared to the PDC group, but the 0.11 m/s median increase also falls in the minimal 
clinically important difference range (0.10 – 0.20 m/s) [214]. Under the ST condition, 
significant improvements were seen in seven out of 13 biomechanical outcome measures. 
All spatiotemporal measures showed significant improvement, as well as hip and trunk 
rotation ROM, and NJ. Improvement in lower extremity gait function in those with PD 
due to an exercise intervention is consistent with previous studies [125], [136], [158], 
[159], [194], [215]. Although upper extremity gait function is less critical for a successful 
walking motion and rarely investigated in interventional studies, it can be an indicator of 
global deficit [54], [124]. Similar to different biomechanical measures describing the 
quality of walking gait for the lower extremities, PL and NJ demonstrate differences in 
arm swing function. 
Although differences in PL did not reach statistical significance, there was a 
significant decrease in NJ in the PDE group compared to the PDC group, indicating an 
increase in smoothness of movement. It has been suggested that declines in arm swing 
are related to rigidity [216], a symptom affecting all aspects of gait. Therefore, positive 
changes observed in arm swing may be linked to changes in gait. Furthermore, these 
changes may be centrally mediated, suggested by the lack of participation of the upper 
extremity in the intervention [28]–[30], [150]. Crenna et al. suggest that projections from 
the basal ganglia to the cervical spinal cord are regarded as less evolutionarily crucial as 
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compared to projections to lumbo-sacral segments, explaining the early appearance of 
arm swing deficits in PD, as well as its limited improvements due to dopaminergic 
therapy or deep brain stimulation [58]. Since prioritization of gait function lies with the 
lower limb first, changes seen in the upper limb may signify a more robust change. 
Interestingly, the PDE group in Figure 16a shows a collection of individuals reaching 
higher levels of improvement in PL than what is seen in the PDC group. These results in 
addition to improvements in NJ, suggest further investigation of the mechanics of arm 
swing as a result of exercise intervention and its role on overall motor function.    
Improvements in gait function due to high-intensity exercise are encouraging in 
terms of supplementing current treatment methods for PD symptom relief. Understanding 
how exercise effects gait in objective detail will contribute to the understanding of 
specific aspects of gait improvement, and how it impacts movements of daily activities. 
Successful walking is important for individuals to carry out daily tasks safely and 
effectively. It is well understood that individuals with PD experience increased gait 
declines under DT conditions, which poses another obstacle for successful walking. 
Therefore, the presence of significant improvements in gait measures under DT 
conditions suggests sustained motor improvement, and results that are clinically and 
practically relevant to the everyday lives of those struggling with PD. All DT conditions 
showed improvements in spatiotemporal and lower extremity joint kinematics, 
demonstrating the ability to sustain benefits from exercise across additional cognitive 
loading across various aspects of executive function.  
 Changes in arm swing not only manifest with the presence of PD [54], [55], but it 
can also change under conditions of increased cognitive load [115], [124]. This 
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connection of a relatively passive movement during gait to neurological function might 
serve as a marker for centrally mediated changes [28]–[30], [150]. Declines in 
smoothness of arm swing movement in PD has been shown to worsen under DT 
conditions, suggesting cognitive loading impacts movement quality [115] as well as 
magnitude. Similar to lower extremity measures, NJ has shown improvement across ST 
and two of the DT conditions, suggesting that centrally mediated improvements remain 
under cognitively taxing conditions.  
 Due to the significant findings comparing the PDE and PDC group, the results 
were expanded to compare the PDE group to the HC group.  Changes in walking speed 
typically includes proportional changes in overall biomechanics, such as joint angles and 
step length [217]. Therefore, increases in biomechanical measures are to be expected as 
walking speed increases. With PD however, the gait patterns are not simply characteristic 
of slowed gait. The combination of decreased speed with little to no change in cadence, 
decreased joint ROM, increased stance phase and decreased step length indicate a 
trademark pattern of walking known as “shuffle gait” [213]. Compared to the HC group, 
the PDE group at baseline walked significantly slower, spent a larger portion of the gait 
cycle with both feet on the ground in stance phase, and had smaller step lengths. This 
indicates that the PDE group took smaller, quicker steps than healthy peers, and had less 
overall knee ROM.  
The change in gait characteristics exhibited by the PDE group were not only 
significant compared to the PDC group, but they were also particularly interesting when 
compared to healthy older adults. As mentioned, the PDE group demonstrated typical PD 
related gait deficits compared to the HC group. At EOT, the PDE groups not only 
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improved, but they also were no longer significantly different from the HC group in gait 
speed, cadence, stance phase, step length and knee ROM. This is similar to the effects of 
dopaminergic therapy for some studies [11], [12], and shows greater improvement than 
others [46], [47]. Exercise studies with animal models have shown increased 
neurotrophic factors, such as brain- and glial-derived neurotrophic factors (BDNF and 
GDNF), contributing to neuroprotection of existing nigrostriatal pathways, and 
regeneration of dopaminergic axons [218]. Detailed structural and chemical neural 
changes due to exercise are difficult to obtain and corroborate with animal model results; 
however, peripheral BDNF has been shown in increase in human exercise studies [218]. 
The results of this study mimicking the effects of dopaminergic medication while “off” 
medication may be explained by these previous findings. Arm swing function, however, 
remains significantly worse in PD than HC, even after intervention. Further studies are 
warranted to investigate arm swing as it relates to alternative treatments for PD.     
 The results of this study coincide with previous studies regarding decreased motor 
function under DT conditions in PD [109]–[111], [119]. Despite the regularity of the 
speed of the treadmill potentially providing external cuing and regulating walking 
patterns [219], significant changes occurred. Interestingly, cadence increased 
significantly in all three DT conditions for the PDE group at baseline and EOT, even 
though the speed maintained the same from ST to DT. The PDC group also experienced 
significant increases in cadence at EOT testing. Step length and stance phase also 
followed patterns of decline under DT conditions, however these measures did not reach 
significance. In previous studies, gait declines under DT conditions include changes in 
speed [111], [114], [220]–[222], which cannot decipher whether the declines are due to 
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general slowed walking speed, or gait characteristics are actually changing. The results 
found in this study suggest that changes in gait performance from ST to DT conditions 
signifies a change in gait pattern, independent of gait speed. Changes in upper extremity 
independent of speed, under DT conditions has been found in previous studies [115], 
[124], and now the decoupling of lower extremity measures adds greater understanding to 
the breakdown of the interconnected rhythmic nature of walking when cognitive loading 
in increased.  
 The CV outcome measures did not result in any significant differences. The 
predicted cause of this finding is similar to the DTC findings. The constant speed of the 
treadmill may have regulated gait movements, therefore altering any potential changes in 
variability [219].     
 The results of the cognitive test scores were contradictory to the hypothesis 
predicting increases in cognitive function, as well as changes in dual-tasking strategies. A 
“posture second” DT strategy is common with PD, where individuals prioritize the 
cognitive task over the motor task. The safety features of the CAREN system may have 
contributed to a feeling of security, therefore allowing subjects to adhere to a posture 
second strategy.  
CHAPTER V: Conclusion 
 Gait and balance measures have shown improvements after a high-intensity 
cycling exercise intervention in PD. Balance recovery after a perturbation has shown a 
decrease in COPex, suggesting less compensatory movements and, potentially, improved 
balance control. Walking also showed marked improvements in speed and quality of gait 
movement under both ST and DT conditions.   
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 The ability to recover from destabilization is essential for avoiding falls and 
injury. People with PD have an increased fall risk compared to healthy older adults [77], 
therefore efforts to decrease the risk of falling and resultant injuries are particularly 
important in the PD population. Since dopaminergic therapy cannot be relied upon to aid 
in balance improvement  [47], [68], other therapies and interventions need to be 
investigated for their potentials in improving dynamic postural stability. The results from 
this study point towards positive effects from exercise intervention, suggesting that the 
neural effects of exercise impact non-dopaminergic pathways. The effects of Lewy 
bodies on PD symptoms is not as prominently studied as the effects from basal ganglia 
dysfunction, yet it may point to discrepancies between dopaminergic therapies and 
remaining symptoms [40]. Brain-derived neurotrophic factor increases in the central 
nervous system after aerobic exercise, and has a positive effect on synaptic plasticity 
[223]. Although research investigating the effects of exercise on Lewy bodies in the brain 
is sparse [224], the results from this study suggest further investigation.  
Spatiotemporal outcome measures are common to describe biomechanical data; 
however, jerk has shown to provide additional information about movement quality, 
especially in PD [115], [225]. Jerk has shown to differentiate PD patients from healthy 
controls in static balance studies [226]–[228], and with the addition of marker data to a 
perturbation study on the CAREN system, this knowledge could be expanded to include 
jerk under dynamic balance conditions.  
 In addition to balance recovery, healthy gait function is also important for fall 
avoidance. Safe, successful gait not only minimizes injury, it can increase self-efficacy 
for physical activity in older adults and encourages continual physical activity [229]. 
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Conscious gait strategies have proven successful in improving gait in PD such as external 
cueing and thoughtful stepping [230]; however, everyday situations do not always lend 
themselves to gait focused thoughts while traversing. The ability to complete a cognitive 
task while walking is crucial to daily activities, even tasks as simple as remembering a 
room number while walking through a large building. Compensatory gait strategies that 
require additional cognitive resources risk competing with the cognitive tasks commonly 
encountered in real world situations, leaving either the cognitive task or gait function to 
suffer. Parkinson’s disease medications provide symptom relief and help deter gait 
declines; however, these declines may still be present with dopaminergic medication 
[11], [46], [47]. The abstract nature of stationary cycling translating to balance and upper 
extremity improvements suggests neural changes worth further exploration. The ease of 
execution and positive side effects of high-intensity cycling make for an attractive 
supplemental PD treatment option.   
 High-intensity exercise interventions that demonstrate improved function in “off” 
medication conditions may potentially have an additive affect to levodopa/carbidopa 
medications, as suggested from increases in motor functions while “on” medication, seen 
in previous studies [158], [159], [194]. The potential structural improvements in 
nigrostriatal projections from an exercise intervention [218] may increase motor function 
improvements when coupled with additional dopamine via medication. To better 
understand the effects of intervention on specific balance recovery and gait parameters, 
future studies are needed that include analysis under both “off” and “on” conditions.    
 The resources necessary for detailed motion capture analysis are not attainable 
nor feasible for a wide population of individuals. Efforts are being made to enable small, 
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portable technology to provide specific measures that can infer gait function [231]–[233] 
which can expand the usage of gait function as a clinical tool. As the understanding of the 
implications of arm swing develops, it has the potential to provide valuable information 
for gait analysis [115], [124] in a concise manner. The results from this study suggest that 
further investigation of arm swing as it relates to gait, cognition, and interventions is 
warranted.  
  Limitations exist within this project. The PD population for both exercise and 
control groups were comprised of mild to moderately affected individuals, and it is 
unclear if a more severe population would demonstrate different results from an exercise 
intervention. Information concerning the presence of clinical cognitive impairment was 
not collected, which may have shown a relationship in different cognitive test abilities. 
During balance data collection with the Time to Stable application, some participants 
took a step to catch their balance, or grabbed onto the handrails. It was instructed to avoid 
these movements and return to their original position as quickly as possible if this does 
occur; however, suppressing these automatic responses was difficult for some 
individuals. Steps or handrail grabs were recorded manually, however no correction or 
data segregation was made based on these actions. Future studies could investigate 
potential differences in trials with catching actions versus those without. Marker 
occlusion of some degree was present in most gait trials. Much of this was corrected 
within the HBM, or was fixed manually via post processing; however, some data was 
lost. Most of the marker occlusion was a result of clothing coverage. Future studies 
should provide motion capture suits to ensure the best methods of data collection.   
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APPENDIX A 
 
 
Time to Stable outcome data  
 
 Baseline EOT 
 Acceleration Level (m/s2) Acceleration Level (m/s2) 
Group 0.25 0.5 1.0 0.25 0.5 1.0 
PDE 3.04 4.58 a 4.30 a 2.73 3.17 c 3.44 a 
PDC 4.30 5.98 5.05 a 3.65 3.71 4.61 
HC 2.91 3.72 4.84    
 
 PDE PDC 
 Acceleration Level (m/s2) Acceleration Level (m/s2) 
Outcome 0.25 0.5 1.0 0.25 0.5 1.0 
ΔTTS -0.15 -1.61 -0.64 -0.70 -1.03 -0.43 
 
Median results in seconds. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s 
disease control group; HC, healthy control group; ΔTTS, change in Time to Stable from 
baseline to end of treatment; xa, significant difference compared to 0.25 of same session; 
xb, significant difference compared to 0.5 of same session; xc, significant difference 
compared to baseline, significant at 0.05 level.  
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APPENDIX B 
 
Center of pressure excursion data   
 
 PDE PDC HC 
Acceleration 
Level 
Baseline 
 
EOT Baseline EOT  
0.25 m/s2 1.79 (0.33) 1.67 (0.36) 1.63 (0.22) 1.64 (0.38) 1.88 
(0.29) 
0.5 m/s2 2.03 (0.40) 1.69 (0.36) 1.69 (0.29) 1.64 (0.37) 1.95 
(0.25) 
1.0 m/s2 1.92 (0.33) 1.84 (0.44) 1.78 (0.26) 1.61 (0.28) 2.13 
(0.17) 
 
Mean (SD) results in meters. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s 
disease control group; HC, healthy control group; EOT, end of treatment. 
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APPENDIX C 
 
Sample size of biomechanical outcome measures  
 
 PDE PDC HC 
Δ   
ST 
BACK  SUB VERB ST BACK  SUB VERB ST BACK SUB VERB 
Gait speed 
(m/s) 
14    14    14    
Cadence 
(steps/min) 
14 14 14 14 14 14 14 14 14 14 14 14 
Stance Phase 
(% gait cycle) 
14 14 14 14 14 14 14 14 14 14 14 14 
Normalized 
step length 
(step/leg length) 
12 13 13 13 14 14 14 14 14 14 14 14 
Ankle ROM 
(degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Knee ROM 
(degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Hip ROM 
(degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Trunk rotation 
ROM (degrees) 
13 13 13 13 14 14 14 14 14 14 14 14 
Pelvic tilt ROM 
(degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Pelvic obliquity 
ROM (degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Pelvic rotation 
ROM (degrees) 
14 14 14 14 14 14 14 14 14 14 14 14 
Normalized PL 
(PL/arm length) 
13 13 13 13 13 13 13 13 14 14 14 14 
Normalized 
jerk  
13 13 13 13 13 13 13 13 14 14 14 14 
 
Right and left sides were collapsed when applicable, out of 14 participants maximum. 
PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC, 
healthy control group; PL, normalized path length; NJ, normalized jerk; ROM, range of 
motion; CV, coefficient of variation; ST, single-task; BACK, N-back dual-task; SUB, 
serial-7 subtraction dual-task; VERB, verbal fluency dual-task. 
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APPENDIX D 
 
Change from baseline to EOT outcome measures 
 
 PDE PDC 
Δ  ST BACK  SUB VERB ST BACK SUB VERB 
Gait speed (m/s) 0.11    -0.05 *    
Cadence (steps/min) 4.52 3.05 3.00 3.64 -3.00 * -0.51 -0.52 -2.01 
Stance Phase (% gait 
cycle) 
-1.69 -1.27 -1.58 -1.43 0.46 * 0.04 -0.10 * 0.36 * 
Step length (% leg 
length) 
11.49 7.73 7.13 8.50 -0.19 * -3.24 * -2.01 * -1.31 * 
Ankle ROM (degrees) 0.65 1.52 1.36 1.87 -0.52 -2.13 * -1.94 -2.26 
Knee ROM (degrees) 1.19 1.93 1.94 2.09 -1.05 -1.80 * -1.51 * -0.77 
Hip ROM (degrees) 3.04 2.03 2.56 2.56 -0.44 * -0.23 * -0.51 * -0.02 * 
Trunk rotation ROM 
(degrees) 
1.35 2.15 1.66 1.79 -0.16 * -0.23 -0.73 0.25 
Pelvic tilt ROM 
(degrees) 
-0.27 -0.60 -0.24 -0.17 2.07 2.65 1.99 2.61 
Pelvic obliquity ROM 
(degrees) 
-0.37 -0.20 -0.01 -0.03 -0.12 -0.81 -1.02 -0.55 
Pelvic rotation ROM 
(degrees) 
0.79 0.61 0.36 0.46 1.06 0.11 0.44 0.96 
PL (% arm length) 9.12 -0.56 1.92 -0.01 -1.97 -1.11 -4.00 -5.43 
NJ  -
144.98 
-83.23 -151.91 -128.00 297.33 
* 
214.81 
* 
157.84 
* 
206.94 
CV Stance phase 0.02 -0.47 -0.42 -0.51 -0.21 -3.60 -0.50 -0.18 
CV Step length -0.07 -1.41 -1.60 -1.30 -0.10 -0.23 0.32 0.18 
CV Ankle ROM -0.80 -0.75 -0.42 0.44 0.68 -0.99 -0.01 0.26 
CV Knee ROM -0.16 -0.40 -0.26 -0.29 0.64 -0.45 0.09 0.32 
CV Hip Rom -1.21 -0.96 -0.93 -0.36 0.23 -1.04 -0.46 0.15 
CV PL -2.07 0.28 1.88 -1.13 -1.04 1.28 -2.60 -0.21 
 
Median results. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease 
control group; HC, healthy control group; PL, normalized path length; NJ, normalized 
jerk; ROM, range of motion; CV, coefficient of variation; ST, single-task; BACK, N-
back dual-task; SUB, serial-7 subtraction dual-task; VERB, verbal fluency dual-task; *, 
significant difference between PDE and PDC groups at p < 0.05 level.  
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APPENDIX E 
 
 
Comparison between Parkinson’s disease exercise and healthy control groups  
 
Outcome measure PDE - baseline PDE - EOT HC 
Speed (m/s)  0.875 1.03 1.25 a 
Cadence (steps/min) 99.01 103.00  109.99 a  
Stance Phase (% gait cycle)  67.85 66.09  65.54 a 
Step length (% leg length)  61.10 74.90  78.12 a 
Ankle ROM (degrees) 28.46 28.73 31.37 
Knee ROM (degrees) 54.35 57.13 60.49 a  
Hip ROM (degrees)  37.45 39.98  42.38 
Trunk rotation ROM (degrees) 12.02 13.24 17.23 
Pelvic tilt ROM (degrees)  4.09 4.08 4.95 
Pelvic obliquity ROM (degrees)  6.46 6.65 9.11 a,b 
Pelvic rotation ROM (degrees) 6.50 7.65  9.05 a 
PL (% arm length)  43.50 54.39 91.62 a,b 
NJ  1815.81 1786.51 1402.74 a,b 
 
PDE, Parkinson’s disease exercise group, PDC, Parkinson’s disease control group; HC, 
healthy control group; PL, normalized path length; NJ, normalized jerk; ROM, range of 
motion; xa, significant difference compared to PDE at baseline; xb, indicates significant 
difference compared to PDE at EOT, significance at p < 0.05 level. 
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APPENDIX F 
 
Dual-task effects, PDE and PDC groups 
 PDE 
 Baseline EOT 
 ST BACK  SUB VERB ST BACK SUB VERB 
Cadence (steps/min) 99.01 104.48 * 101.51 * 104.01 * 103.00  108.50 * 105.00 * 109.00 * 
Stance Phase (% gait 
cycle) 
67.85 67.23 67.32 67.35 66.09 66.16 65.79 65.96 
Step length (% leg 
length) 
61.10 58.81 59.66 58.09 74.86 70.00 72.87 70.90 
Ankle ROM 
(degrees) 
28.46 27.46 27.59 28.11 28.73 29.17 28.48 28.80 
Knee ROM (degrees) 54.35 53.14 * 53.06 52.30 57.13 56.10 * 57.45 55.84 * 
Hip ROM (degrees) 37.45 36.82 38.26 37.42 39.98  38.48 39.06 38.13 
Trunk rotation ROM 
(degrees) 
11.20 9.78 * 10.53 10.17 * 13.24 12.50 12.21 12.25 
Pelvic tilt ROM 
(degrees) 
4.09 4.27 4.45 4.12 4.08 3.59 3.89 3.96 
Pelvic obliquity 
ROM (degrees) 
6.46 5.89 6.43 5.83 6.65 6.57 7.13 6.70 
Pelvic rotation ROM 
(degrees) 
6.50 5.95 6.29 5.66 7.65 7.18 7.51 7.33 
PL (% arm length) 43.50 29.94 30.45 28.25 54.39 43.82 41.43 38.62 
NJ  1815.81 1816.62 1975.04 2045.72 1786.51 1739.88 1945.70 1849.99 
         
  
 
PDC 
 Baseline EOT 
 ST BACK  SUB VERB ST BACK SUB VERB 
Cadence (steps/min) 106.98 107.49 105.48 106.98 98.46 104.48 * 100.49 102.49 
Stance Phase (% gait 
cycle) 
65.97 65.98 66.68 65.98 66.30 66.14 66.21 66.03 
Step length (% leg 
length) 
60.55 61.86 61.00 63.02 53.49 50.90 52.08 54.96 
Ankle ROM 
(degrees) 
28.17 28.00 29.15 28.50 26.94 24.70 26.22 25.75 
Knee ROM (degrees) 55.51 55.96 55.80 55.97 55.11 53.81 54.63 54.21 
Hip ROM (degrees) 35.66 34.59 33.84 34.13 34.80  33.75 * 32.75 * 33.27 * 
Trunk rotation ROM 
(degrees) 
11.70 9.98 9.67 10.79 10.68 8.61 10.26 10.04 * 
Pelvic tilt ROM 
(degrees) 
4.89 4.89 5.06 4.89 4.64 4.38 4.38 4.35 
Pelvic obliquity 
ROM (degrees) 
5.48 5.58 6.20 5.72 5.07 4.82 * 4.92 * 4.96 
Pelvic rotation ROM 
(degrees) 
5.75 5.50 6.71 6.13 6.95 6.39 6.58 6.52 
PL (% arm length) 45.40 35.46 * 33.71 37.87 42.03 26.91 * 26.66 26.82 * 
NJ  1559.58 2089.28 2303.49 2366.72 1744.00 2870.67 2618.71 2914.70 
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Median results. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease 
control group; HC, healthy control group; PL, normalized path length; NJ, normalized 
jerk; ROM, range of motion; ST, single-task; BACK, N-back dual-task; SUB, serial-7 
subtraction dual-task; VERB, verbal fluency dual-task; *, significant difference between 
task and ST condition of same session at p < 0.05 level.  
 
